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Background: Genetic variants within genes involved in fibrillogenesis, including a polymorphism in 
the COL5A1 gene, have previously been associated with anterior cruciate ligament (ACL) injury 
susceptibility, specifically in females. Proteoglycans have also been implicated in having important 
functions in fibrillogenesis and maintaining the structural integrity of ligaments. Moreover, their 
content appears to be lowered in ruptured ACL tissue in comparison to non-ruptured controls. Genes 
encoding proteoglycans are therefore plausible candidates to be investigated for an association with 
ACL injury susceptibility. Sequence variants within genes encoding the proteoglycans aggrecan 
(ACAN: rs2351491, rs1042631, rs1516797), biglycan (BGN: rs1126499, rs1042103), decorin (DCN: 
rs13312816, rs516115), fibromodulin (FMOD: rs7543148, rs10800912) and lumican (LUM: 
rs2268578) were consequently investigated.  
 
Methods: A case-control genetic association study was conducted where 227 participants with 
surgically diagnosed ACL ruptures (ACL group), including a non-contact mechanism of injury subgroup 
(NON: 126 participants), and 234 controls without any history of ACL injury were genotyped for ten 
polymorphisms in the five proteoglycan genes, using standard PCR based methods. Inferred 
haplotypes were constructed for specific regions encompassing the ACAN, BGN, DCN, FMOD and 
LUM-DCN genes, and inferred allele constructs were created to investigate gene-gene interactions 
between the proteoglycans and the previously associated COL5A1 gene, using the genotype data 
obtained for the respective loci. Statistical analyses determined whether genotype, allele, haplotype 
and/or allele construct frequencies differed significantly between cases and controls. Sex-specific 
associations, as well as associations by mechanism of injury were also investigated. 
 
Results: Independent associations were noted for two of the polymorphisms investigated. The G 
allele of ACAN rs1516797 was significantly under-represented in the controls (p=0.024; OR=0.72; 95% 
CI:0.55-0.96) compared to the ACL group. For DCN rs516115, the GG genotype was significantly over-
represented in female controls (p=0.015; OR=9.23; 95% CI:1.16-73.01) compared to the ACL group; 
and the AA genotype was significantly under-represented in the controls (p=0.013; OR=0.33; 95% 
CI:0.14-0.78) compared to the female NON subgroup. No further independent associations were 
identified for the investigated variants.  
 
Inferred haplotype analyses implicated regions overlapping the ACAN, BGN, and LUM-DCN genes in 
ACL injury susceptibility. The T-C-T and T-C-G ACAN inferred haplotypes (rs2351491 C>T - rs1042631 
xvi 
 
T>C - rs1516797 T>G) were significantly over-represented (p=0.001) and under-represented 
(p=0.005) in the CON group respectively, in comparison to the ACL group. The BGN (rs1126499 C>T - 
rs1042103 G>A) C-G inferred haplotype was significantly over-represented (p=0.027) in the CON 
group in comparison to the ACL group for female participants only. The T-A-G LUM-DCN inferred 
haplotype (rs2268578 T>C - rs13312816 A>T - rs516115 A>G) was significantly under-represented 
(p=0.038) in the CON group in comparison to the ACL group.  
 
Several gene-gene interactions were also noted in this dissertation. Inferred allele constructs 
identified gene-gene interactions between (i) BGN and DCN, (ii) BGN and COL5A1, (iii) DCN and 
COL5A1, and (iv) all three of these genes collectively, which may potentially be involved in the 
modulation of ACL injury susceptibility. 
 
Conclusion: The evidence suggests that ACAN rs1516797 and DCN rs516115 are independently 
associated with ACL injury risk. In addition, the inferred haplotype analyses have implicated defined 
genomic boundaries overlapping the (i) ACAN, (ii) BGN and (iii) LUM-DCN genes which require further 
interrogation to identify the potential causal genomic motifs associated with ACL injury susceptibility. 
The potential gene-gene interactions noted between the various proteoglycan genes and COL5A1 
further highlight the complex myriad of interactions between the structural components of the 
extracellular matrix of ligaments, which may collectively contribute to our understanding of the 
pathobiology of ACL injury susceptibility. The novel results presented are collectively providing 
evidence contributing to the current hypothesis that genetic sequence variability within genes, such 
as the proteoglycan encoding genes, may potentially modulate the ligament fibril properties thereby 
effecting ACL injury susceptibility. 
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Introduction and scope of dissertation 
  
The regular participation in physical activity is an important part of maintaining a healthy lifestyle.(1,2) 
There is however an increased risk of sustaining a musculoskeletal soft tissue injury when 
participating in either competitive or recreational activities.(3) Musculoskeletal soft tissue injuries 
collectively refer to acute and overuse injuries of the tendons, ligaments and skeletal muscles, and 
may occur in either active or sedentary individuals.(4,5) Some of the extensively studied common 
tendon and ligament injuries include the Achilles tendon of the ankle,(6) the patella tendon of the 
knee, the extensor carpi radialis brevis tendon of the elbow,(7) the rotator cuff tendons of the 
shoulder,(8) the anterior cruciate ligament (ACL) of the knee (9) and the ankle ligaments.(10) The exact 
aetiology of these injuries remains unknown,(11-16) but several intrinsic and extrinsic risk factors have 
been implicated in the mechanism of injury for each.(14,16-21)  
 
The ACL is a major intra-articular ligament which stabilises the knee joint and contributes to its 
normal function.(22) Rupture to the ACL accounts for the majority of ligament injuries in the knee 
joint (23) and although relatively uncommon in the general population, they are of high prevalence in 
individuals participating in sporting activities,(24) particularly female athletes.(25-28) It has been 
estimated that 250,000 new ACL ruptures occur annually in the United States alone.(29) Rupture of 
the ACL is considered one of the most severe and detrimental injuries sustained in sports;(30) costly 
reconstructive surgery and rehabilitation is required to treat the injury, and an individual who has 
sustained an ACL rupture is at greater risk of developing osteoarthritis (OA) of the knee joint.(31,32) 
 
Intrinsic risk factors for ACL injuries can be broadly classified into four categories: anatomical, 
hormonal, neuromuscular, and more recently established genetic risk factors.(21,33) Harner et al. 
(1994) was the first to suggest that there may be a familial predisposition to ACL injuries,(34) and in 
2005 Flynn et al. showed that individuals with an ACL tear were twice as likely to have a first-degree 
relative with an ACL tear, in comparison to controls.(9) Since then, several genetic variants within 
candidate genes have been implicated as contributing factors to the risk of sustaining an ACL 
injury,(35-39) highlighting the polygenic nature of this multifactorial condition. 
 
Interestingly, polymorphisms within several genes (COL1A1, COL5A1 and COL12A1) encoding 
proteins implicated in the regulation of fibrillogenesis, have been associated with ACL injury risk in 
several candidate gene association studies.(35-38) Proteoglycans are a unique family of proteins within 
the extracellular matrix (ECM) having decidedly diverse functions which include playing a role in 
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fibrillogenesis.(40) Appropriately regulated fibrillogenesis is essential for the development of regular 
collagen fibrils and normal fibrillar organisation.(41-44) This is vital for the proper functioning of 
ligaments and thus important components of the fibril, such as proteoglycans, warrant investigation. 
 
Increasing our understanding of the biological consequences of the numerous complex interactions 
between the components of the ECM in regulating fibrillogenesis, should assist us in elucidating the 
aetiology of ACL injuries. The identification of additional genetic risk factors that contribute to 
sustaining an ACL rupture will further add to the understanding of the mechanisms underlying this 
injury. This is essential for the development of preventative measures so as to reduce the incidence 
of this detrimental injury. Comprehending the pathobiology of ACL injuries may also lead to the 
development of improved treatments after injury. Following the approach of a candidate gene based 
genetic association study; the primary aim of this dissertation was (i) to identify novel genetic loci 
within proteoglycan encoding genes, which may predispose an individual to sustaining an ACL 
rupture. In addition, this dissertation aimed to identify (ii) genomic intervals overlapping the 
proteoglycan genes, and (iii) potential gene-gene interactions between proteoglycans and the 
COL5A1 gene, which may highlight the biological mechanisms involved in the modulation of ACL 
injury susceptibility.  
 
In preparation for the experimental chapters of this dissertation, Chapter 1 reviews the current 
literature. This review provides an overview of the anatomy and function of the ACL (Section 1.1), 
injury to the ACL (Section 1.2) and the risk factors associated with ACL injuries (Section 1.3). This 
section also details the genetic risk factors that have previously been associated with ACL injury risk 
(Section 1.3.2). The proteoglycans, the focus of this dissertation, are also introduced in Chapter 1 
(Section 1.4), and the novel candidate genes to be implicated in ACL injury susceptibility are 
identified and discussed (Section 1.5). The structure and functions of proteoglycans are explored, as 
well as the structural role of proteoglycans in ligaments (Section 1.6) and proteoglycans in the 
injured state (Section 1.7).  
 
Subsequent experimental chapters present the candidate gene approach followed to fulfil the aims 
of (i) investigating loci within proteoglycan encoding genes, and (ii) regions encompassing the 
proteoglycan encoding genes, for an association with ACL injury susceptibility in a Caucasian South 
African population (Chapter 2). Chapter 3 aimed (iii) to explore the possible interaction of 
proteoglycan encoding genes with the previously ACL risk associated COL5A1 rs12722 polymorphism 
in the modulation of ACL injury susceptibility. 
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Chapter 4 concludes the novel findings of this dissertation and the limitations. It further highlights 
the role of genetics in ACL ruptures and the possible clinical implications of the findings of this 
dissertation. This chapter also presents some of the potential future directions of research in this 
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1.1 The anterior cruciate ligament 
 
Ligaments are dense bands of collagenous tissue which extend over a joint and are attached to the 
bone at either end.(45) The primary function of ligaments is to mechanically stabilise joints and guide 
them through their normal range of motion when a tensile load is applied.(45) The viscoelastic 
behaviour of ligaments also enables them to provide joint homeostasis. Lastly, ligaments function in 
joint proprioception: the conscious perception of limb position in space.(45)  
 
Throughout the human body ligaments differ in size, shape, location and orientation. They are 
organised hierarchically into interconnected groups of parallel fibre bundles which run along the 
long axis of the ligament. These fibrous bundles, or fascicles, are made up of collagen fibres, which in 
turn consist of smaller collagen fibrils.(45) The collagen bundles run parallel to the long axis, and 
exhibit waviness or ‘crimp’ along the length. Crimp refers to the regular pattern of the matrix and 
has a biomechanical role concerning the ligaments loading state: when an appropriate load is 
applied to the ligament it can ‘uncrimp’, elongate and lengthen to a point of stiffness or restraint 
without sustaining fibrous damage. Applying further strain beyond the point of stiffness may result 
in the rupture of the ligament.(45,46)  
 
Ligaments are more complex at the microscopic level: cells, called fibroblasts, compose a small part 
of the total structure, and are responsible for synthesising and maintaining the ECM which 
surrounds the cells.(47) Biomechanically ligaments are composed of two-thirds water and one-third 
solid components. The water is responsible for the cellular function and viscoelastic behaviour of 
ligaments.(45) The solid component of the ECM consists primarily of collagen, which accounts for 
approximately 75% of the dry weight (85% of which is type I collagen and the remainder is made up 
of type III, V, VI, XI and XIV). The balance of the solid component consists of elastin, glycoproteins, 
and glycosaminoglycans (GAGs).(45)  
 
The ACL is a major intra-articular ligament, which connects the femur to the tibia (Figure 1.1) and 
together with the posterior cruciate ligament (PCL) stabilises the knee joint as it moves through its 
normal range of motion. It functions in preventing excessive anterior translation of the tibia on the 
femur, as well as limiting internal rotation of the tibia and providing posteroanterior knee 
stability.(48) Because of the position and functions of this ligament, it is one of the most frequently 
injured structures during sporting activities.(49) 
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Figure 1.1: Basic anatomy of the right knee joint displaying the anterior cruciate ligament and 
surrounding structures. The femur and tibia, as well as the posterior cruciate ligament, medial 
collateral ligament and lateral collateral ligament are shown.(50)  
 
 
Proximally the ACL originates from the posterior medial surface of the lateral femoral condyle where 
it is attached in a semi-circle;(51) the ACL fans out to the larger and stronger distal attachment which 
is on the anterior portion of the intercondylar eminence of the tibia.(52,53) The tibial insertion is 
approximately 120% broader than that of the femoral insertion.(54) The ACL orientates in a spiral 
across the joint due to its attachments: from the femur it runs anteriorly, medially, and distally to 
the tibia.(55) The PCL attaches from the posterior region of the tibial intercondylar eminence to the 
femoral medial condyle. The ACL and PCL are completely covered in synovium, hence why the ACL is 
classified as extra-synovial but intra-articular.(56) The medial collateral ligament (MCL) and lateral 
collateral ligament (LCL) are extra-articular (Figure 1.1) and are important for knee stability during 
inward (varus) and outward (valgus) angulation of the joint.(52) 
 
The ACL has a mean length of 32 mm and its width ranges from 7 to 12 mm.(55) Collagen fibrils 
composing the ACL are grouped to form 1 to 20 µm fibres surrounded by other ECM proteins. The 
fibres subsequently merge to form larger sub-fasicular units that can fan out into functional 
bands.(45) The ACL contains two distinct functional bands or bundles of fibres which differ in tension 
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during varying ranges of motion: the anteromedial bundle (AMB) lengthens and tightens during knee 
flexion, while the posterolateral bundle (PLB) shortens and becomes slack; the PLB tightens during 
knee extension.(53,57,58) The PLB controls anterior translation between 0 and 30˚ flexion and the AMB 
controls translation after 30˚ flexion. These bundles are named after the locations of their tibial 
insertions. The fibres of the AMB have their origin in the most proximal part of the femur and insert 
at the anteromedial part of the tibia, while fibres of the PLB originate from the distal part of the 
femur and insert on the posterolateral part of the tibia.(59) These collagenous bands attach to the 
bones by transitional zones of fibrocartilage and mineralized cartilage.(56,60) The forces that are 
transmitted through these bundles differ with varying knee-joint positions.(61) Controversy exists in 
the literature as to whether the ACL is composed of three bundles rather than two. To date the 
understanding is that the ACL has two distinct functional bundles (53,55,59,62,63) but three distinct 
bundles when examined anatomically.(64-66) 
 
Macroscopically, the ACL is composed of multiple fascicles surrounded by a connective tissue 
sheath. The fascicles are composed of sub-fasciculi, ensheathed by loose connective tissue, which 
are in turn composed of sub-fascicular units also surrounded by a loose connective tissue consisting 
of type II collagen. These sub-fascicular units are made up of fibres of collagen fibrils, the basic unit 
of the ACL.(59,67) Two types of fibrils compose the ACL: large inhomogeneous fibrils resist high tensile 
stress (approximately 50%), and small homogeneous fibrils maintain the structural organisation of 
the ligament (approximately 44%). These fibrils thus compose approximately 94% of the ACL tissue 
while the remaining 6% constitutes the cells and matrix components.(67) The ACL matrix consists of 
collagens (with type I collagen being a major component), proteoglycans, GAGs, glyco-conjugates 
and elastic components.(59,67) Proteoglycan content of the ACL is highly variable across the 
fibrocartilage and at the bone attachment sites.(68) 
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1.2 Injury to the ACL 
 
ACL injuries are the most common ligamentous injury of the knee.(56) Traumatic joint injuries are 
commonly responsible for ligament tears, which may be either partial or complete ruptures. These 
ligament tears are usually owed to the application of an excessive external load to the limb; however 
the ACL can also be injured without an external force being directly or indirectly applied to the knee 
joint, but rather due to internal forces generated within the joint.(52) Ultimately the ACL will fail when 
a biomechanical load placed upon it exceeds the maximum load that it can withstand.(69) Since the 
ACL acts to resist anterior tibial translation and internal tibial rotation, it is predominantly ruptured 
when the femur is externally rotated in relation to a fixed lower extremity or if the tibia is internally 
rotated relative to the femur; the ACL is also at greater risk of injury during excessive knee 
extension.(56,70)  
 
Most ACL ruptures involve the middle substance of the ligament and infrequently the femoral or 
tibial attachments.(56) When an ACL rupture occurs it is likely that a secondary injury to the menisci, 
articular cartilage or other ligamentous structures will take place. Meniscal injuries are reported in 
approximately 50-70% of patients with ACL injuries and MCL injuries occur in approximately 18-22% 
of patients with ACL injuries; however these can also occur in individuals without ACL injuries.(56,71) 
 
It has been estimated that 250,000 new ACL ruptures occur annually in the United States,(29,33) 
however it is difficult to determine ACL injury incidence rates in many countries because not all 
individuals with an ACL injury seek medical care.(72) ACL ruptures are considered one of the most 
severe and detrimental injuries sustained in sports,(30) as the ligament does not heal and 
reconstructive surgery and rehabilitation is required to treat this injury,(73) a costly expense. 
Following an ACL rupture, an athlete will be forced to miss several months of competitive sport 
which may result in the loss of contracts or sponsorship, and the athlete may never regain their pre-
injured state of fitness or skill.(74) Without reconstructive surgery the knee remains unstable and is 
predisposed to further injury. An estimated 125,000 ACL reconstructions were performed in the 
United States in 2006, and the number of ACL reconstructions taking place appears to be increasing 
annually.(75) The Swedish National ACL Register reported 15,387 primary ACL reconstructions during 
the period from 2005 to 2010,(76) while the Danish ACL reconstruction registry reported 12,193 
primary reconstructions for the same period.(77) 
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When a complete ACL rupture occurs, the ligament rapidly degenerates and thus primary repair 
does not usually provide a pleasing end result.(78,79) The poor healing capacity of the ACL (relative to 
the extra-articular MCL) may be due to the biochemical properties of the ECM, biomechanical forces, 
intra-synovial environment, blood supply or nutrient supply.(78,79) Cellular proliferation, migration, 
collagen synthesis, response to growth factors and variable gene expression may also be responsible 
for the poor healing capability of the ACL.(78-81) 
 
An individual who has sustained an ACL injury is at a greater risk of developing OA of the knee joint 
because of the degenerative changes that take place following the injury.(31,32,82) Lohmander et al. 
(2004) examined female soccer players twelve years after ACL injury and discovered that 82% of the 
participants had radiographic changes in their knee index while 51% met the criteria for radiographic 
knee OA.(83) Even after ACL reconstructive surgery is performed, patients still have degeneration of 
the articular cartilage and symptoms of early onset OA. Emphasis thus needs to be placed on 




 1.2.1 Mechanisms of ACL injury 
 
ACL injuries may occur through contact or non-contact mechanisms, both of which have been 
described as the mechanism of injury in the large majority of participants investigated in the 
experimental chapters of this dissertation. The mechanism of injury for downhill alpine skiing is 
completely different to that of contact and non-contact, and the ACL injury in this case may result 
from several different causes described in detail by Silvers et al. (2007).(52) Contact injuries are due to 
the application of an external force, such as collision with another player or an object in the area of 
activity. These injuries can further be divided into two different mechanisms: direct or indirect 
contact. Direct contact is when an external force is applied directly to the knee that is injured, 
whereas indirect contact is when an external force is applied to the individuals’ body but not directly 
to the injured knee. On the other hand, non-contact ACL injuries are a result of internal forces 
created within the knee joint as a result of the athletes own movements.(33,52) The classification of 
the mechanisms of ACL injury is in accordance with the American Orthopaedic Society of Sports 
Medicine.(33) 
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The majority of reported ACL injuries are caused by non-contact mechanisms.(28,33,84) The frequency 
of non-contact injuries however varies with type of activity: sports that involve landing and pivoting 
have high incidence of non-contact ACL injuries, while contact sports tend to have a lower frequency 
of non-contact injuries and higher frequency of contact injuries.(84) Non-contact injuries usually 
involve sudden deceleration in a single step or stopping action, or quick direction changes, as well as 
cutting or twisting movements. Injury by a non-contact mechanism typically occurs with the knee in 
an extended position, and thus landing from a jump with either near or complete knee and hip 
extension or insufficient flexion, is another cause.(33) If an individual attempts to rapidly decelerate 
or change direction when the foot is fixed and pronated, the tibia is rotated inward or the knee is 
near or at complete extension, it is likely that the ACL will partially or completely rupture due to the 
undesirable torsional force placed on the knee joint.(33,52) 
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1.3 Risk factors associated with ACL injury 
 
Although the precise aetiology remains unknown, multiple risk factors have been implicated in ACL 
injuries.(9,85) Susceptibility to an ACL rupture is understood to be multifactorial, with complex 
interactions between risk factors. Males and females are believed to have separate risk models for 
ACL injury,(86) as females have a 3 fold greater risk of sustaining an ACL rupture in comparison to 
their male counterparts.(28) 
 
Risk factors for multifactorial disorders, including ACL injuries, can be classified into two groups: 
intrinsic and extrinsic. Intrinsic risk factors influence the individual from within and are generally 
non-modifiable, with the exception of weight and body mass index (BMI). Extrinsic risk factors 
impact the individual from the external environment and are generally modifiable.(4) 
 
To date, five different groups of risk factors, one extrinsic and four intrinsic, have been implicated in 
an individual sustaining an ACL injury. The four intrinsic risk factors include: anatomy, hormones, 
neuromuscular factors and genetics.(4,33) These risk factors are not mutually exclusive, but rather 
work in combination to modulate ACL injury susceptibility. One can hypothesise that the interaction 
of risk factors, for example the extrinsic environment and genetics, contribute to the observed inter-
individual variation noted with regards to sustaining an ACL injury. 
 
Individuals or athletes having one or more intrinsic risk factors are considered to be predisposed to 
injury. Exposure of these individuals to extrinsic risk factors increases their susceptibility to 
sustaining an injury. Ultimately the occurrence of an inciting event results in an injury, such as an 
ACL rupture (Figure 1.2).(4,5,87) Note, it is not the risk factors which cause the injury; they simply 
contribute to an individual being more susceptible to injury. The identification of risk factors 
predisposing an individual to injury will aid in understanding the aetiology and biological 
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Figure 1.2: A schematic diagram illustrating the complex multifactorial relationship between intrinsic 
and extrinsic risk factors, and an inciting event that results in an anterior cruciate ligament rupture. 
Intrinsic risk factors can be broadly classified as anatomical, hormonal, neuromuscular, and genetic, 
while extrinsic risk factors involve the environment the athlete is placed in. These risk factors 
predispose an individual to sustaining an ACL rupture. Ultimately an inciting event results in the 
injury of the athlete. Adapted from Meeuwisse et al. (1994)(4) and Collins et al. (2009).(5)  
 
 
 1.3.1 Extrinsic and intrinsic risk factors for ACL injury 
 
An extensive evidence-based review of intrinsic risk factors for ACL injuries has recently been 
published.(21) The intrinsic risk factors will therefore be summarised in this dissertation. Since the 
extrinsic risk factors are not the primary focus of this dissertation, they will also only be summarised 
in the following section. 
 
 
 1.3.1.1 Extrinsic risk factors 
  
Extrinsic risk factors that may affect susceptibility to ACL injuries include the weather, playing 
surface, footwear and prophylactic/functional knee bracing (Table 1.1).(52) 
 
In the analysis of National Football League (NFL) games, it was found that when playing in outdoor 
stadiums, cold weather is associated with a lower risk of ACL injuries in comparison to hot weather; 
this was suggested to be due to lower shoe-surface traction.(88) Evidence suggests that friction is the 
key element playing a role in injury risk with regards to playing surface. Artificial surfaces have been 
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When considering footwear, it is important to note that although increased friction may enhance 
performance and allow more rapid sprinting, stopping and changes in direction, it will also 
unintentionally increase the risk of injury during these movements. It is important to identify optimal 
footwear that will decrease rotational traction in order to try avoid injury, but enhance intermediate 
friction for ideal performance.(91)  
 
Controversy exists regarding the efficacy of the use of knee braces.(92) A study involving a major 
American college football team demonstrated that knee injury incidence, including ACL injury 
incidence, was greater when laterally placed prophylactic knee braces were worn.(93) Another study 
on American football players showed that there is no statistically significant difference in injury rates 
or severities when wearing prophylactic knee braces or not.(94) 
 
 
 1.3.1.2 Intrinsic risk factors for ACL injury 
 
The intrinsic risk factors will be discussed in four categories: anatomical, hormonal, neuromuscular 
(Table 1.1) and genetic risk factors (Table 1.2). Researchers have overwhelmingly shown that female 
athletes have an excessively higher incidence of ACL injuries in comparison to males,(25,27,28,86,95-99) 
and several studies have provided evidence that the female sex is an intrinsic risk factor for ACL 
ruptures.(37,38,100,101) Anatomy, anthropometric, hormonal and neuromuscular disparities may be the 
reasons for the difference in ACL injury susceptibility between men and women. Gwinn et al. (2000) 
showed that overall, female participants had a 2.4 to 1 relative risk of ACL injury in sports and a 9.5 
to 1 relative risk in military exercises in comparison to males. This study was conducted on a United 
States military training cohort with identical facilities for males and females, it was thus suggested 
that intrinsic factors could be the only reason for the increased risk of ACL injury in females.(99) 
 
 
  Anatomical risk factors 
 
Anatomical risk factors include ACL size and geometry, quadriceps angle (Q angle), notch width, 
tibial slope, foot pronation, pelvic tilt, BMI and knee laxity.(33,86) The ACL has sex-based variations in: 
size, females have smaller ACLs;(102) structural properties, females have lower load to failure, 
elongation to failure and energy absorbed at failure;(103) and ultrastructure, females have more 
  Chapter 1
 _________________________________________________________________________________  
11 
 
densely packed collagen fibrils.(104) Thus, anatomical risk factors for ACL injuries differ between males 
and females. 
 
It has been suggested that males and females with ACL ruptures have smaller ACL diameters.(105) 
Several studies have also shown that the ACL diameter and cross-sectional area is smaller for 
females in comparison to males,(52,106,107) perhaps a reason for the higher injury incidence observed 
in females. In addition, the Q angle which is believed to reflect the alignment of the leg, is greater in 
females in comparison to males; this could be another reason why females are at an increased risk 
of ACL ruptures,(108) however there is no definitive evidence of this. 
 
Increased risk of ACL ruptures has further been associated with a smaller femoral intercondylar 
notch width and femoral notch width index.(33,105,109-111) Interestingly, females have a smaller femoral 
intercondylar notch width in comparison to males. Men have a wider ‘U-shaped’ intercondylar 
notch, whereas women have a narrower ‘A-shaped’ notch.(106) Moreover, several other studies have 
also implicated notch opening,(112) lateral condylar width (113) and total condylar width (107) in ACL 
injury susceptibility. There is also an anatomical correlation between height and total condylar width 
in males and females; ACL area is likewise correlated to height in males but not females,(107) thus 
indirectly implicating height in ACL injury risk.  
 
The tibial slope of the ACL is thought to be a risk factor for ACL injuries because an increased tibial 
slope is associated with increased anterior tibial translation which may increase strain on the 
ACL.(114) 
 
Foot and pelvic alignment has also been associated with the risk of ACL ruptures. Increased subtalar 
joint pronation of the foot has been suggested to be associated with an increased risk of ACL 
ruptures (115) because increased pronation results in greater rotation of the knee joint.(116) Females 
characteristically have excessive subtalar pronation in comparison to males.(106) An increase in 
anterior pelvic tilt is also thought to be associated with ACL ruptures because of its effect on the 
alignment on the lower leg.(117) 
 
The risk of ACL injury was previously associated with an increased BMI. One of the reasons for this is 
that individuals with an increased BMI tend to have a more extended knee position when landing.(33) 
Increased BMI has been significantly associated with the risk of ACL ruptures in females, but not with 
males.(105) 
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Generalised joint laxity, an overall measurement of whole body joint laxity or flexibility, has been 
associated with an increased risk of ACL ruptures in both males and females.(105,117) Females 
generally have greater generalised joint laxity in comparison to males.(118) Increased anterior knee 




  Hormonal risk factors 
 
The female menstrual cycle phase was previously highlighted as one of the hormonal risk factors for 
ACL injury.(19) Receptor sites for oestrogen, progesterone and relaxin have been found in the 
ACL,(52,119) and sex hormones have been suggested to affect ACL structure and composition and may 
play a role in the biological processes of the ACL.(119) The fluctuations in oestrogen and progesterone 
during the menstrual cycle may therefore influence the properties of the ACL and a female may thus 
be more susceptible to injury at different stages of the cycle.(26,120-124)  
 
 
  Neuromuscular risk factors 
 
Neuromuscular control is defined as the unconscious efferent response to an afferent signal about 
dynamic joint stability. Efferent signals either involve feedback mechanisms: reactions due to an 
afferent input (force to the joint), or feed forward mechanisms: results of pre-activated preparatory 
activation of muscle. Proprioceptive activities may play a role in injury reduction because they are 
vital for optimal motor performance.(52) Other neuromuscular risk factors proposed for ACL injuries 
include reduced hip and knee flexion angles, increased knee valgus, internal rotation of the femur on 
the tibia, high quadriceps muscle activity in comparison to the hamstrings and inadequate trans-
knee muscle stiffness.(33) These factors pose risks because they cause kinematic and kinetic 
differences during cutting and pivoting or landing from a jump.(33) 
 
Muscular recruitment and strength are critical for knee stability, and an imbalance in quadriceps to 
hamstring strength ratios, especially a weak hamstring, puts the ACL at an increased risk of injury.(52) 
Furthermore, the ACL is strained when landing from a jump with insufficient knee and hip flexion 
due to the increased load on the knee and force from the quadriceps. During flexion in a squat 
position, the loaded hamstring muscle functions together with the ACL to reduce anterior tibial 
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translation and internal tibial rotation.(125) Valgus loading was further implicated as a likely cause of 
injury during sidestepping-cutting manoeuvres, particularly in females.(126,127)  
 
 
Table 1.1: A summary of the risk factors implicated in anterior cruciate ligament injury susceptibility. 
 
Extrinsic risk factors 
Intrinsic risk factors 
Anatomical Hormonal Neuromuscular Genetic 
physical activity sex oestrogen concentration flexion angles COL1A1 
training errors age progesterone concentration knee valgus COL5A1 
weather BMI menstrual cycle phase rotation COL12A1 
playing surface ACL size and geometry  muscular activity MMPs 
footwear knee joint geometry    
knee bracing knee joint laxity    
medication pelvis and foot alignment    
 
Abbreviations: ACL, anterior cruciate ligament; BMI, body mass index; COL1A1, collagen 1 alpha 1 
gene; COL5A1, collagen 5 alpha 1 gene; COL12A1, collagen 12 alpha 1 gene; MMPs, the genes 
encoding the matrix metalloproteinases. 
 
 
  Genetic risk factors  
 
In 2005 Flynn et al. suggested that there is a familial predisposition toward tearing the ACL,(9) as had 
previously been alluded to by Harner et al. (1994).(34) Flynn’s study demonstrated that participants 
with an ACL rupture were twice as likely to have a first-degree relative with an ACL rupture in 
comparison to those participants who had no history of ACL injuries, thus proposing genetic factors 
as risks for ACL injuries. Genetic loci within several genes have since been identified as being 
associated with ACL injury risk. The genes and their associated variants are listed in Table 1.2. These 
case-control genetic association studies were successful in exploiting genetics as a tool for 
identifying plausible pathways that may be contributing to the risk of ACL injuries. Understanding 
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Table 1.2: A summary of the genetic loci and respective polymorphisms previously associated with 
anterior cruciate ligament injuries. 
 
Gene Function Polymorphism 
accession 
number 
Associated injury Reference 
COL1A1 Encodes the pro-α1 
polypeptide of type 
I collagen 
rs1800012 ACL ruptures and 
shoulder dislocations 
ACL ruptures 
Khoschnau et al. (2008)(35) 
 
Posthumus et al. (2009) (36) 





Encodes the pro-α1 





ACL ruptures in 
females 
 
Posthumus et al. (2009)(37) 
 
COL12A1 Encodes the pro-α1 
polypeptide of type 
XII collagen 
rs970547 ACL ruptures in 
females 






Encodes for matrix 
metalloproteinases 

















Abbreviations: ACL, anterior cruciate ligament; COL1A1, collagen 1 alpha 1; COL5A1, collagen 5 alpha 
1; COL12A1, collagen 12 alpha 1; MMP, matrix metalloproteinase. 
 
 
Although genetic risk factors have been considered as a separate category in this dissertation, it is 
important to note that individually the anatomical, hormonal and neuromuscular risk factors are all 
multifactorial phenotypes determined by both genetic and non-genetic factors. Genetic risk factors 
are therefore probably not independent factors but rather part of the traditional three categories of 
mentioned intrinsic factors. For example flexibility is an anatomical risk factor for musculoskeletal 
soft tissue injuries that is influenced by genetics; the COL5A1 gene has been associated with 
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 1.3.2 Genetic loci previously associated with ACL injury risk 
 
 1.3.2.1 COL1A1  
 
The collagen I α1 gene (COL1A1) encodes the α1 chain of type I collagen and regulates the 
production of this fibril forming collagen.(131) Type I collagen is the major protein constituent of 
ligaments, comprising 70-80% of the dry weight.(45) This collagen is a key structural component of 
ligaments, tendons and other non-cartilaginous connective tissues, and is arranged in bundles of 
parallel fibres to make up the tissue.(45) The Sp1 transcription factor binding site polymorphism 
(rs1800012) within intron 1 of the COL1A1 gene is a G>T substitution that has previously been 
associated with cruciate ligament injuries as well as shoulder dislocations in the Caucasian 
population.(35,36,128) The rare TT genotype of this polymorphism was shown to be significantly under-
represented in participants with cruciate ligament ruptures, predominantly ACL, in comparison to 
controls. Although this genotype is rare in the general population, this is still an interesting 
association.(5,35,36,128) The Sp1 transcription factor binding site polymorphism has also been 
associated with several other complex multifactorial phenotypes including OA,(132) osteoporotic 
fractures,(133) lumber disc disease,(134) myocardial infarction (135) and stress urinary incontinence.(136) 
This polymorphism has also been investigated in Achilles tendon injuries but no association was 
identified between rs1800012 and Achilles tendinopathy or Achilles tendon ruptures.(129) The T allele 
of rs1800012 has been proposed to increase the binding affinity of the Sp1 transcription factor, 
causing an increase in COL1A1 gene expression and the construction of a weaker type I collagen 
homotrimer, composed of three α1(I) chains.(133,137) In addition, Ficek et al. (2013) recently 
implicated a haplotype within the promoter of the COL1A1 gene, containing rs1800012 and 
rs1107946, in ACL injury susceptibility.(128)  
 
 
 1.3.2.2 COL5A1 
 
The collagen V α1 gene (COL5A1) encodes the α1 chain of type V collagen. Type V collagen, a minor 
fibrillar collagen, is another structural component of connective tissues which makes up 
approximately 10% of the collagen content in ligaments.(138) Type V collagen intercalates with type I 
collagen and is believed to regulate the collagen fibril diameter.(138) The BstUI restriction fragment 
length polymorphism (RFLP) (rs12722) within COL5A1, is a C>T substitution which localises to the 3’-
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untranslated region (UTR). The CC genotype of this polymorphism was found to be significantly over-
represented in a control group of female participants, while the T allele (CT and TT genotypes) was 
significantly over-represented in a female group with ACL ruptures, when Caucasian females from 
ACL rupture and control groups were compared.(37) The 3’-UTR contains important regulatory 
elements; the T allele of COL5A1 rs12722 is believed to increase COL5A1 mRNA stability, suggesting 
that more α1(V) chain is synthesised.(139) Laguette et al. (2011) have recently identified three 
polyadenylation signals and a functional microRNA (miRNA) binding site for Hsa-miR-608 within the 
3’-UTR of COL5A1.(139) The COL5A1 gene has also been associated with phenotypes other than soft 
tissue injuries, including range of motion and endurance running performance.(140) 
 
 
 1.3.2.3 COL12A1 
 
The collagen XII α1 gene (COL12A1) encodes a structural component of ligament fibrils, the α1 chain 
of type XII collagen. Type XII collagen mediates fibril interactions with extracellular and cell surface 
molecules.(141) This collagen associates with the surface of collagen fibrils, in order to mediate 
interactions, and is a member of the fibril associated collagens with interrupted triple helicies 
(FACIT) family. Sequence variants within COL12A1 have also been investigated for an association 
with ACL ruptures.(38) The COL12A1 AluI RFLP (rs970547) is a G>A substitution that is significantly 
associated with ACL ruptures in Caucasian females; the AA genotype of this polymorphism was 
significantly over-represented in a female ACL injured group in comparison to controls in a study by 
Posthumus et al. (2010).(38) This polymorphism (rs970547) lies within exon 65 of COL12A1 and the 
non-synonymous G>A substitution (the GG genotype is rare) results in a glycine to serine amino acid 
change. Although this substitution results in a non-polar neutral glycine amino acid being substituted 
by a neutral polar amino acid, the variation has no known functional significance. However, it has 
been suggested that this polymorphism may cause an altered type XII collagen to be produced, 
which may change the interactions of this peptide with other proteins and modify the biomechanical 
properties of the collagen fibril.(38)  
 
 
 1.3.2.4 MMPs (11q22) 
 
Matrix metalloproteinases (MMPs) are the key regulators of ECM degradation and remodelling and 
are thus critical to ligament homeostasis and integrity.(142) Four polymorphisms within genes 
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encoding MMPs,(MMP1 rs1799750, MMP3 rs679620, MMP10 rs486055 and MMP12 rs2276109) 
which are all positioned on chromosome 11q22, have been investigated for an association with ACL 
ruptures in Caucasian individuals. Genetic variants within this region have previously been 
associated with multiple complex phenotypes including OA,(143) rheumatoid arthritis (RA),(144) lumbar 
disk degeneration,(145) idiopathic scoliosis,(146) aseptic prosthetic loosening (147) and Achilles 
tendinopathy.(142) Matrix metalloproteinase 1 (MMP1) encodes a secreted matrix enzyme which 
breaks down the interstitial collagen types I, II, and III.(148) The MMP1 rs1799750 single nucleotide 
polymorphism (SNP) is a deletion/insertion of a G nucleotide, which is known to be functional; the 
2G allele causes significantly higher transcription of the gene in comparison to the 1G allele.(149) 
Matrix metalloproteinase 3 (MMP3) encodes the MMP3 enzyme which degrades collagen types II, 
III, IV, IX, and X, proteoglycans, fibronectin, laminin and elastin and can also activate other MMPs.(150) 
The MMP3 gene has previously been associated with Achilles tendinopathy.(142) Matrix 
metalloproteinase 10 (MMP10) encodes MMP10 which degrades proteoglycans and fibronectin.(151) 
Both MMP3 rs679620 and MMP10 rs486055 are non-synonymous polymorphisms which result in an 
amino acid change; however the functional significance of both these SNPs is yet to be defined.(152) 
Matrix metalloproteinase 12 (MMP12) encodes MMP12 which degrades soluble and insoluble 
elastin,(153) and the rs2276109 T>C substitution polymorphism within this gene was found to be 
independently associated with ACL ruptures.(39) This polymorphism lies within the upstream 
regulatory promoter region of the MMP12 gene and is proposed to have functional effects on the 
gene. The A allele is believed to increase the activity of the transcription factor activator protein-1 
and increase MMP12 gene expression.(154) Two inferred haplotypes constructed using different 
combinations of the variants in the MMP1, MMP3, MMP10 and MMP12 genes listed above, were 
also found to be associated with ACL injury risk.(38)  
 
The genetic association studies discussed have provided cumulative evidence that genetic risk 
factors are an important component of the intrinsic risk factors that may predispose an individual to 
sustaining an ACL injury. These studies have also been vital in identifying structural components of 
the ACL that contribute to the molecular mechanisms of injury risk. Injury to the ACL is however a 
multifactorial condition subjected to multiple risks; it is thus probable that there are multiple genes 
contributing to the aetiology of this injury. 
 
The collagen genes are vitally important in fibrillogenesis as well as the formation of collagen fibrils 
of regular organisation. Mutations within the collagen genes are associated with several connective 
tissue disorders which result in the loss of mechanical functions of tendons and ligaments.(140,155,156) 
  Chapter 1
 _________________________________________________________________________________  
18 
 
Mutations in the COL5A1 gene, for example, have been shown to cause classic Ehlers–Danlos 
syndrome (EDS).(157) The proteoglycans, found within the ECM, are also important structural 
constituents of connective tissues, such as the ACL, having significant roles in fibrillogenesis, ECM 
remodelling as well as cell signalling within the ligament.(158) Mutations within proteoglycans have 
also been implicated in connective tissue disorders,(159,160) and murine tissues deficient in certain 
proteoglycans have similar physical phenotypes to humans with classic EDS: fibrillogenesis is 
compromised resulting in collagen fibrils of highly irregular diameters and abnormal fibrillar 
organisation.(41-43)  
 
Genes biologically relevant to ACL injuries, encoding proteins and enzymes involved in the structure 
and function of the ACL tissue, as well as signalling molecules within the tissue, should be 
investigated for associations with ACL injury risk. The genes encoding proteoglycans are therefore 
viable candidates to be investigated for an association with ACL injury susceptibility. 
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1.4 Introduction to proteoglycans 
 
Proteoglycans, also known as mucoproteins, are glycosylated proteins that vary in size and structure. 
They are found throughout the human body, on the cell surface and within the ECM. Proteoglycans 
are composed of a core protein peptide, ranging from 10 kDa to >500 kDa in size, to which one or 
more GAGs are covalently attached. GAGs are linear carbohydrate polysaccharide chains formed 
from repeating disaccharide sugar units. The most common GAG structures include chondroitin 
sulfate (CS), dermatan sulfate (DS), heparin, heparan sulfate (HS), keratan sulfate (KS) and a non-
sulfated GAG, hyaluronic acid (HA).(161) Either one or both of the sugars in the GAG unit have a 
sulfate group, rendering the proteoglycan highly negatively charged. This is essential for the function 
of proteoglycans which bind water giving the ECM gel like properties, thus improving the 
biomechanical properties of the connective tissue and providing the collagen fibrils with high 
capacity to resist compressive and tensile forces.(162) Proteoglycans have vast molecular diversity and 
biological functions because the various protein cores can have one or more different GAG chains 
attached.(163) They play an important role in maintaining the structural integrity of tissues by 
stabilising the collagenous network. Proteoglycans are also involved in cell signalling pathways as 
well as the regulation of ionic homeostasis and collagen fibrillogenesis, which is essential for 
development and tissue repair.(158,162) 
 
Proteoglycans can be broadly classified into three major groups according to their protein core, 
structure and function: the small leucine-rich proteoglycans (SLRPs), the large modular 
proteoglycans, and the cell-surface proteoglycans (Table 1.3).(163) It must however be noted that it is 
possible to have overlapping with this classification.  
 
Several proteoglycans such as versican and decorin are widely expressed in various tissues, however 
some proteoglycans are tissue specific. Neurocan, brevican and neuroglycan C for example are 
specific to the central nervous system (CNS).(164) The distribution of proteoglycans in tendons and 
ligaments is subject to which areas are affected by different mechanical forces. In tendons for 
example, regions subjected to longitudinal/tensional forces are rich in the SLRP decorin although 
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Table 1.3: Classification of the proteoglycans identified in ligaments and tendons, as reviewed in 
current literature. 
 
*** These classes of proteoglycans have not been described in tendons and ligaments 
‡ Detected fibromodulin in the knee cartilage of canines following unilateral ACL transection 
˜ Keratocan identified in bovine tendons 
* Detected increase in aggrecan in the articular cartilage adjacent to the ACL following injury to the ligament 
† Detected decrease in lubrican concentration in synovial fluid of knee following an ACL rupture 
® Detected proteoglycan 4 in bovine tendon by immunohistochemical analyses 
Abbreviations: CS, chondroitin sulfate; DS, dermatan sulfate; DSPG3, dermatan sulfate proteoglycan 3; GAGs, 
glycosaminoglycans; HA, hyaluronic acid; HS, heparan sulfate; KS, keratan sulfate. 
Proteoglycan GAGs Ligament Tendon 
SMALL LEUCINE-RICH PROTEOGLYCANS (SLRPs) 
Class I 
Biglycan CS/DS 
Somerman 1990;(166) Yukawa 2001;(167) 
Ilic 2005;(168)  Young 2011 (169)  
Vogel 1993;(170) Berenson 1996;(171) 
Waggett 1998;(172) Samiric 2004 (173)  
Decorin CS/DS 
Larjava 1992;(174) Yukawa 2001;(167)  
Ilic 2005;(168) Henninger 2007;(175)  
Young 2011 (169)  
Vogel 1993;(170) Berenson 1996;(171) 
Waggett 1998;(172) Samiric 2004 (173) 
Asporin  Yamada 2001(176)  
Class II 
Fibromodulin KS ‡ Liu 2003 (177) Waggett 1998 (172) 
Lumican KS Chatuparisute 2012 (178) Waggett 1998 (172) 
Keratocan KS  ˜ Rees 2009 (179) 
Class III 
Epiphycan (DSPG3) CS/DS Deere 1996 (180)   
Class IV *** 
Class V ***  
MODULAR PROTEOGLYCANS 
Hyalectans/Lecticans (HA/lectin binding) 
Versican CS/DS 
Larjava 1992;(174) Ilic 2005;(168)  
Young 2011 (169)  
Waggett 1998;(172) Corps 2004;(181) 
Samiric 2004 (173)  
Aggrecan CS/KS 
Ilic 2005;(168) *Nelson 2006;(182)  
Young 2011 (169)  
 
Vogel 1994;(183) Berenson 1996;(171) 
Samiric 2004 (173)  
Non-hyaluronic acid-binding *** 
CELL-SURFACE PROTEOGLYCANS 
Syndecans (1-4) CS/HS Worapamorn 2000 (184) Sawaguchi 2006 (185) 
Glypicans (1-6) HS Worapamorn 2000 (184) Sawaguchi 2006 (185) 
Betaglycan CS/HS Worapamorn 2000 (184) Sawaguchi 2006 (185) 
CD44   Sawaguchi 2006 (185) 
Other proteoglycans 
Proteoglycan 4 (Lubrican) CS/KS †Elsaid (186) Marcelino 1999;(187) ®Rees 2002 (188)  
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The SLRPs can be divided into five subfamilies (Classes I-V) based on homology, cysteine-rich regions 
and chromosomal organisation.(163) SLRPs are composed of a small protein core that contains 
leucine-rich repeats (LRRs), N-terminal cysteine clusters and a minimum of one GAG side chain 
attached (Figure 1.3).(163,189,190) A distinct feature of Class I-III SLRPs is that they contain an ‘ear’ 
repeat. This is the second to last LRR (the longest LRR) that is proposed to maintain the 
conformation of the core protein.(191)  
 
SLRPs not only have structural roles, but constitute a network of signalling roles as well.(60) They 
regulate collagen fibril growth, fibril organisation and ECM assembly. They are therefore critical for 
the structural integrity of ligaments and other connective tissues.(40) SLRPs are also involved in the 
regulation of cell-matrix interactions by directly binding plasma membrane receptors and 
pericellular matrix molecules.(40) As a result, they can influence cellular differentiation, apoptosis, 
proliferation and migration through various signalling pathways and interactions. They therefore 
play an important role in maintaining tissue homeostasis, as well as having roles in tissue repair and 
regeneration/remodelling in pathological conditions.(192) SLRPs also have tissue-specific structural 
and signalling functions in various microenvironments that are defined by the differences in their 
protein cores and GAG side chains.(40) 
 
Class I SLRPs include biglycan, decorin, asporin and extracellular matrix protein 2.(60) Typically, the N-
termini of Class I SLRPs have a cysteine cluster that forms two disulphide bonds. Class I SLRPs all 
have a small exonic organisation, eight exons, with the intron/exon junctions being highly 
conserved.(163,193) Biglycan is expressed in skin, tendons and ligaments, as well as in bone and dentin 
matrices.(194) This proteoglycan is involved in the regulation of collagen fibrillogenesis and interacts 
with collagen fibrils.(195) Decorin is found in the tensile regions of tendons, ligaments and synovial 
capsule,(196) and is important in tissue development and assembly as well as regulating collagen 
fibrillogenesis.(197) Asporin, originally named periodontal ligament-associated protein 1,(60) has also 
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Figure 1.3: Structure of the small leucine-rich proteoglycans, displaying the important leucine-rich 
repeats, cysteine residues, and glycosaminoglycan side chain attachment sites.(198) Examples of Class 
I (decorin and biglycan) and Class II (fibromodulin, lumican and keratocan) small leucine-rich 
proteoglycans are displayed. Class III small leucine-rich proteoglycans are structurally similar. 
 
 
Class II SLRPs include fibromodulin, lumican, proline/arginine-rich end leucine-rich repeat protein 
(PRELP), keratocan and osteomodulin.(60) These SLRPs have clusters of tyrosine sulfate residues at 
their N-termini (Figure 1.3), and bind primarily KS or an unsulfated form of keratan. The genes 
encoding Class II SLRPs have a highly conserved, very small exonic arrangement; only three exons, 
with the large central exon encoding most of the LRRs.(163,193) Fibromodulin helps define tissue 
integrity within ligaments and regulates collagen fibrillogenesis.(177,199,200) Lumican is expressed in 
various tissues, including ligaments, where it is important in fibrillogenesis and cellular 
proliferation.(178,199) Keratocan has also been identified in soft connective tissues such as tendons, 
but functions primarily in the cornea.(179)  
 
Class III SLRPs include epiphycan, opticin and mimecan.(60) This class is classified by having a genomic 
arrangement comprising seven exons, and a low number of LRRs, only seven.(163,193) Epiphycan, also 
known as dermatan sulfate proteoglycan 3, has been identified in ligaments and has three GAG 
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binding sites, two N-glycosylation sites, a poly-glutamic acid stretch, and six cysteine residues.(180) 
This proteoglycan is important in cartilage development and remodelling.(201) 
 
Class IV SLRPs consist of chondroadherin, nyctalopin and tsukushi, while class V SLRPs include 
podocan and podocan-like protein I.(60,163,193) Neither Class IV nor Class V SLRPs have yet been 
identified as being expressed in musculoskeletal soft tissue, such as tendons and ligaments, and are 
therefore beyond the scope of this review.  
 
The heterogeneous modular group of large proteoglycans are classified as the assembly of several 
protein molecules in an elongated and often highly glycosylated structure.(202) The modular 
proteoglycans can be divided into two subfamilies: the hyalectans (HA- and lectin binding 
proteoglycans), and the non-HA-binding proteoglycans.(203) The non-HA-binding modular 
proteoglycans include perlecan, agrin, the testicans, phosphocan and several collagens. The non-HA-
binding modular proteoglycans have not been identified in tendons or ligaments and are therefore 
beyond the scope of this review; they have recently been reviewed by Schaefer et al. (2010).(163) 
 
Four proteoglycans make up the group of hyalectans: versican, aggrecan, neurocan and brevican. 
The hyalectan proteoglycans are described as having a tri-domain structure composed of a central 
domain with N- and C-terminal globular regions on either side (Figure 1.4). The central domain 
contains multiple attachment sites for GAGs, the N-terminal domain binds HA, and the C-terminal 
domain interacts with lectins (Figure 1.4).(163,202,203) Neurocan and brevican are CNS proteoglycans 
that inhibit neuronal attachment and neurite growth.(203) 
 
The largest hyalectan is versican; it is present in a variety of soft tissues and is found within purely 
tensional regions of ligaments and tendons.(172,204) Versican is expressed by fibroblasts and functions 
in cell adhesion, migration and proliferation, as well as ECM assembly and fibrillogenesis of the 
elastic fibres.(205) Alternative RNA splicing occurs between the two large exons encoding the GAG 
attachment sites of versican to give rise to four different mRNA transcripts.(205,206) Because of its 
complex structure, versican is able to interact with various ECM molecules and cell surface 
proteins.(207) The variable expression of versican allows this proteoglycan to be a crucial regulator of 
cell-matrix interactions.(203)  
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Figure 1.4: Structure of the large hyalectan proteoglycans, aggrecan and versican, displaying the 
central, N-terminal and C-terminal domains.(208) Abbreviations: C, complement regulatory protein-
like module; EGF, epidermal growth factor-like repeat; GAG, glycosaminoglycan-attachment domain; 
HABR, hyaluronic acid-binding region; LEC, C-type lectin-like module. 
 
 
Aggrecan exists in the form of aggregates stabilised by a link protein; it is composed of HA and up to 
one hundred aggrecan molecules (Figure 1.4).(209) This proteoglycan is expressed in the CNS, 
cartilage, ligaments and the tensional regions of tendons,(169,183,210) and regulates cartilage 
development, growth and homeostasis. Aggrecanases are responsible for the degradation of 
aggrecan in tendons and ligaments via proteolysis of specific Glu-Xaa bonds.(173) Cleavage of the 
aggrecan core protein by aggrecanases and other MMPs results in fragments of various sizes that 
can be retained and accumulate in the cartilage.(209) Chondrodysplasias, such as spondyloepiphyseal 
dysplasia, result from mutations in human, mice, and chicken aggrecan genes.(211-213) 
 
The cell surface proteoglycans include those that are membrane spanning, and the 
glycosylphosphoinositide (GPI)-linked proteoglycans. The membrane spanning syndecans and the 
GPI-linked glypicans are the major HS proteoglycans found on the cell surface, where HS acts as a co-
receptor that enables ligand encounters with signalling receptors.(214) Other membrane spanning 
proteoglycans include betaglycan, cell surface glycoprotein CD44 version 3, chondroitin sulfate 
proteoglycan 4, chondroitin sulfate proteoglycan 5 and receptor protein tyrosine phosphatase. The 
syndecans appear to be involved in complex signalling processes that regulate cellular proliferation, 
differentiation, adhesion and migration.(163,214,215) The GPI-linked cell surface proteoglycans include 
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the six members of the glypican family as well as a spliced form of brevican. Glypicans, like 
syndecans, are also involved in the regulation of several signalling pathways including fibroblast 
growth factor and transforming growth factor-β (TGF-β).(163,216) 
 
Proteoglycan 4 (PG4), also known as lubrican, has an approximate molecular mass of 345 kDa,(217) 
and is suggested to prevent cell attachment to the articular surface of synovial joints, as well as 
lubricating articular cartilage at the synovial interface.(187,218) PG4/lubrican has been identified in 
both human (187) and bovine (188) tendons, as well as being observed to increase in the surrounding 
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1.5 Genetic association studies and candidate genes 
 
The aim of genetic association studies is to identify an association between one or more genetic 
variants and a trait.(219) Performing genetic association studies using common allelic variants is 
currently still cheaper than the complete sequencing of genes. Genetic association studies can be 
used as a powerful tool in mapping a region biologically relevant to a multifactorial condition, which 
can facilitate the development of specific treatments or personalised medicine. RA is a classic 
example of this approach being successfully applied.(220) Several variants and risk alleles within genes 
involved in the CD40 pathway have been implicated in the development of RA by genetic association 
studies. Following fine mapping and deep sequencing of the CD40 risk locus, a potential causal SNP 
underlying the association of this locus with RA was identified. Functional studies implicated the risk 
allele in causing increased CD40 protein on the cell surface, and a reporter assay was used to 
examine the effect of several chemical compounds and drugs on a cell line with the risk allele. Two 
chemical compounds were identified to disrupt the amount of CD40 on the cell surface and are now 
being considered as possible treatments in the development of RA.(220) This is proof-of-concept that 
human genetics and association studies in particular, are an important first step in identifying 
potential novel loci to be targeted in therapies for complex traits such as RA. To date, case-control 
genetic association studies are one of the most successful methods in identifying genetic variants 
and regions that underlie complex multifactorial conditions, such as ACL injuries.(221) This approach 
has also been successfully used for musculoskeletal soft tissue injuries such as Achilles 
tendinopathy.(139) 
 
Case-control genetic association studies examine polymorphisms between a group of people with a 
condition, such as an ACL injury, and a group without any history of the condition, which serves as a 
control. Statistical analyses are used to determine whether a particular genotypic variation is 
significantly over or under-represented in one of the groups. If so, this gene and its variation within, 
is said to be associated with either an increase or decrease in susceptibility to the injury. The 
advantage of case-control genetic association studies is that they exploit the differences between 
the genetic profile of affected and unaffected individuals. The disadvantage is that they do not prove 
that a variation is the cause of the injury, it is merely an association which provides evidence for the 
involvement of the investigated gene and warrants further investigation.(222) 
 
Analysis of association can be informative even when based on non-functional genetic variants.(223) 
Association analyses of a functional genetic variant allows it to be directly associated with the cause 
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of the phenotype, and genetic variants in linkage disequilibrium (LD) may be indirectly 
associated.(219,224) 
 
A candidate gene approach explores and selects genes and polymorphisms based on a prior 
hypothesis that the genes or polymorphisms have a potential biological role in the phenotype being 
researched.(225) It is a hypothesis driven approach. The genes selected are generally related to the 
biology of the condition or similar conditions and therefore have a higher probability of being 
associated with the phenotype of interest than any other random gene present in the genome.(226) 
 
The proteoglycans act as both structural and signalling molecules in ligaments, regulating various 
biological pathways that include matrix remodelling.(158) Variations in the genes encoding 
proteoglycans may potentially alter the biomechanical properties of ligaments, thus contributing to 
ACL injury susceptibility. After investigating the proteoglycans present in ligaments and tendons 
(Table 1.3) aggrecan, biglycan, decorin, fibromodulin and lumican appeared to be biologically 
relevant to ACL pathology, and the genes encoding these proteins were therefore chosen as 




 1.5.1 Aggrecan 
 
Aggrecan, a large proteoglycan, is one of the major components of cartilage, functioning in cartilage 
elasticity and compressibility.(227) The core protein of aggrecan has a molecular mass of 
approximately 230 kDa and can have multiple GAG chains attached to it. Three globular domains, 
G1, G2, and G3, and two GAG attachment domains (KS and CS domains) found between the G2 and 
G3 domains comprise the core protein of aggrecan. An interglobular domain lies between G1 and 
G2.(227) The coding sequence of the globular domains shows high homology among species, while the 
KS and CS GAG attachment domains are diverse.(228)  
 
Aggrecan plays a major structural role in ligaments and the tensional regions of tendons, and 
regulates cartilage development, growth and homeostasis.(169,210) The gene encoding aggrecan 
(ACAN) (Figure 1.5) lies on chromosome 15q26.1. It is 70.89 Kb in length, contains 16 exons and has 
9 possible transcripts.(229) A missense pathogenic mutation within the aggrecan gene (rs121913568) 
has been implicated in osteochondritis dissecans and spondyloepimetapheseal dysplasia.(159,160) 
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Several other polymorphisms within the aggrecan gene have previously been associated with (i) 
sickle cell anaemia,(230) (ii) height in individuals of European (231) and African ancestry,(232) (iii) lumbar 
disc degeneration (233) and (iv) high myopia in individuals from China.(234) 
























Figure 1.5: Schematic diagram of the aggrecan gene (ACAN) with some of the common polymorphisms shown. The grey boxes indicate the exons, and the 
horizontal lines that connect the exons represent the introns. The black boxes represent the untranslated regions. The polymorphisms chosen for 
investigation in this dissertation (rs2351491, rs1042631 and rs1516797) are indicated in bold. (Bioinformatic resources ncbi.nlm.nih.gov, ensembl.org and 
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 1.5.2 Biglycan 
 
Biglycan is a 38 kDa SLRP consisting of a LRR protein core which is covalently bound to two 
negatively charged CS or DS GAGs on serine 42 and 47.(163,235) This proteoglycan is expressed in skin, 
cartilage, bone and other connective tissues including ligaments.(41) When biglycan is localised in 
bone and dentin matrices, CS GAGs are predominantly bound, however when found in soft 
connective tissues such as skin, tendons and ligaments biglycan is bound by DS GAGs.(236) The 
function of biglycan is to regulate collagen fibrillogenesis and structure by interacting with collagen 
fibrils;(195) this allows biglycan to maintain the ECM structure of bone and connective tissues.(237) This 
proteoglycan is believed to influence the viscoelasticity of tendons,(238) as well as osteoblast function 
and positively regulate bio-mineralisation through processes that alter the activity of growth 
factors.(239)  
 
The mechanism of action of the biglycan protein or its GAGs at the pathological level is not clear. 
Biglycan can however interact with growth factors such as TGF-β which suggests its involvement in 
modulating growth factor availability to cells.(189) Biglycan expression is increased by TGF-β (240) and 
biglycan itself, dose-dependently decreases the expression of TGF-β.(241) This proteoglycan also acts 
as an endogenous ligand for the toll-like receptors (TLRs) and is capable of producing a pro-
inflammatory response.(242) 
 
The gene encoding biglycan (BGN) lies on chromosome Xq28. It is 14.62 Kb in length, contains 8 
exons and has 7 possible transcripts (Figure 1.6).(243) The biglycan promoter has several Sp1 
transcription factor binding sites and several transcription start sites. There are also six interleukin 
(IL)-6 response elements within the biglycan promoter that generally induce biglycan expression 
when IL-6 is bound.(244) Biglycan expression is decreased by the binding of tumor necrosis factor-α 
(TNF-α) to the promoter region.(245) Biglycan mRNA levels and proteoglycan biosynthesis are 
invariably up-regulated by TGF-β.(246,247) Although biglycan is on the X chromosome, it is suggested to 
behave like a pseudo-autosomal gene that escapes X inactivation and has an active copy on the Y 
chromosome. There is however also evidence that biglycan does undergo X inactivation, and does 
not have a Y chromosome homologue.(248) The pseudo-autosomal expression of biglycan could be 
attributed to a gene or several genes adjacent to biglycan that escape X inactivation and control the 
transcriptional activity of the gene.(248) Polymorphisms within the biglycan gene have not yet been 
implicated in any multifactorial phenotypes. 






















Figure 1.6: Schematic diagram of the biglycan gene (BCN) with some of the common polymorphisms shown. The grey boxes indicate the exons, and the 
horizontal lines that connect the exons represent the introns. The black boxes represent the untranslated regions. The polymorphisms chosen for 
investigation in this dissertation (rs1126499 and rs1042103) are indicated in bold. (Bioinformatic resources ncbi.nlm.nih.gov, ensembl.org and 
pga.gs.washington.edu (SeattleSNPs) were used to create this Figure). 
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 1.5.3 Decorin 
 
The major proteoglycan found in tensile regions of fibrous connective tissues such as tendons, 
ligaments and synovial capsule is decorin.(196) Decorin is a SLRP with a molecular mass of 
approximately 40 kDa. This proteoglycan has important roles in tissue development and assembly, 
and binds to collagen to regulate collagen fibrillogenesis.(197) Decorin functions in maintaining tissue 
integrity by binding fibronectin and thrombospondin. This proteoglycan also regulates collagen 
degradation,(249) cell growth (250) and extracellular signalling.(251) The LRRs of the core protein of 
decorin facilitate its non-covalent binding to the surface of fibrillar collagens, predominantly type I 
collagen, where it can retard the rate and degree of collagen fibrillogenesis.(252-255) The binding of 
decorin to collagen V has either a direct effect on the collagen, or mediates the interaction of 
collagen V with other molecules.(256) Fibril-collagen interactions are highly important with regards to 
the ligaments response to loading.(257) Decorin can also bind collagens II, III, VI and XIV and can thus 
affect a variety of ECM components.(258) The GAG chains of decorin function in maintaining the inter-
fibrillar spacing of the collagen fibrils,(252) and the coordinated expression of decorin and associated 
collagen fibrils may therefore regulate ordered matrix assembly.(43)  
 
Decorin can bind all three isoforms of TGF-β,(259) sequestering the molecule in the ECM.(260) This 
proteoglycan is also involved in cellular proliferation and the cell cycle,(261) angiogenesis (262) and 
apoptosis.(263) Decorin can also act as a damage-associated molecular pattern (DAMP), interacting 
with the immunity receptors TLR 2 and 4, therefore regulating a sterile inflammatory response 
within connective tissue.(264) 
 
The gene encoding decorin (DCN) (Figure 1.7) lies on chromosome 12q21.33. It is 37.88 Kb in length, 
contains 8 exons and has 22 possible transcripts.(265) It is interesting to note that DCN gene 
expression can be regulated via several cell-signalling responses such as TNF-α inducible nuclear 
proteins, IL-1β,(266) IL-I, IL-4 (267,268) and TGF-β.(269) The collective evidence is suggesting that decorin 
plays a critical role in matrix assembly regulation through its myriad of potential interactions with 
ECM components. It is therefore not surprising that several signalling mechanisms are in place to 
tightly regulate the synthesis of this proteoglycan in response to the ever changing cellular 
environment. Interestingly, there have been no published reports describing polymorphisms within 
the DCN gene to be implicated in any multifactorial phenotypes although various studies have 









Figure 1.7: Schematic diagram of the decorin gene (DCN) with some of the common polymorphisms shown. The grey boxes indicate the exons, and the 
horizontal lines that connect the exons represent the introns. The black boxes represent the untranslated regions. The polymorphisms chosen for 
investigation in this dissertation (rs13312816 and rs516115) are indicated in bold. (Bioinformatic resources ncbi.nlm.nih.gov, ensembl.org and 
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 1.5.4 Fibromodulin 
 
Fibromodulin is expressed in collagenous connective tissues, including ligaments, and plays a role in 
defining tissue integrity (199) and regulating collagen fibrillogenesis.(200) As a SLRP, fibromodulin is 
important for maintaining tissue homeostasis, as well as for tissue repair and regeneration in normal 
and pathological conditions.(192)  
 
The gene encoding fibromodulin (FMOD) lies on chromosome 1q32. It is 10.86 Kb in length, contains 
3 exons and has 6 possible transcripts (Figure 1.8).(273) Genetic association studies have not yet 











































Figure 1.8: Schematic diagram of the fibromodulin gene (FMOD) with some of the common polymorphisms shown. The grey boxes indicate the exons, and 
the horizontal lines that connect the exons represent the introns. The black boxes represent the untranslated regions. The polymorphisms chosen for 
investigation in this dissertation (rs7543148 and rs10800912) are indicated in bold. (Bioinformatic resources ncbi.nlm.nih.gov, ensembl.org and 
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 1.5.5 Lumican 
 
Lumican is a SLRP,(274) which is expressed in various different tissues including skin,(275) arteries,(276) 
intervertebral discs,(277) bone,(278) aorta,(279) articular cartilage,(280) tendons and ligaments.(172,178) 
Lumican has an important role in collagen fibrillogenesis (199,275) as well as functioning in tissue 
homeostasis by regulating cellular proliferation,(281) migration (281,282) and adhesion.(282) The core 
protein of lumican has a molecular weight of approximately 40 kDa and like most other SLRPs, has 
three major domains: a negatively charged N-terminal domain; tandem LRRs adapted for protein–
protein interactions (where lumican can interact with fibrillar collagens and modulate fibril 
formation); and a C-terminal domain containing two conserved cysteine residues.(283)  
 
The gene encoding lumican (LUM) lies on chromosome 12q21.3-q22. It is 9.2 Kb in length, contains 3 
exons and has 3 possible transcripts (Figure 1.9).(284) This gene has previously been associated with 
high myopia susceptibility in a Han Chinese population,(285) as well as being associated with 
susceptibility to pathological myopia in the Northern Han Ethnic Chinese.(286) A particular 
polymorphism (rs2268578) has been associated with breast cancer (271) as well as the risk of 
























Figure 1.9: Schematic diagram of the lumican gene (LUM) with some of the common polymorphisms shown. The grey boxes indicate the exons, and the 
horizontal lines that connect the exons represent the introns. The black boxes represent the untranslated regions. The polymorphism chosen for 
investigation in this dissertation (rs2268578) is indicated in bold. (Bioinformatic resources ncbi.nlm.nih.gov, ensembl.org and pga.gs.washington.edu 
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1.6 The structural role of proteoglycans 
 
Proteoglycans are a diverse group of molecules that function in both cell signalling pathways and in 
maintaining the structural integrity of tissues.(162) The proteoglycans form part of the ECM, which is 
an integral part of any connective tissues ability to withstand mechanical loads. The multivalent 
binding capabilities of proteoglycans assist the ECM by attaching to and stabilising collagen fibrils in 
an organised manner.(255) The interaction of DS proteoglycans with collagen fibrils leads to increased 
ECM stability,(288) and the negative charge of SLRPs attract water preventing fusion of the fibrils and 
segregation of the extra-fibrillar molecules.(189) Fibril-proteoglycan interactions are one of the 
important interactions that take place during a connective tissues response to loading (Figure 
1.10).(289) 
 
One of the important functions shared by several SLRPs is the regulation of collagen fibrillogenesis. 
The SLRPs are key regulators of collagen fibril assembly as they can delay fibril formation.(44,290) Type 
I and type V collagens are closely regulated by SLRPs during fibrillogenesis; the proteoglycans 
interact with the collagen fibres, forming the basis of the structural organisation of the tissue.(254,291) 
The SLRPs regulate collagen fibrillogenesis by directly interacting with the collagens via their central 
domains,(44) and aggrecan functions in maintaining the structural integrity of ligaments by 
associating with the collagen network, although the interaction of aggrecan with the collagen 
network is not fully understood (Figure 1.10).(195,197,256) Decorin influences collagen fibril diameter (292) 
and shape by restricting lateral growth,(44) and biglycan inhibits collagen fibrillogenesis in vitro, 
although the interaction of biglycan with collagens is not yet well characterised. During 
fibrillogenesis, both lumican and fibromodulin inhibit lateral growth, fibril thickness, and may also 
influence fibril number.(290) The GAGs of SLRPs are involved in the regulation of fibrillogenesis and 
also impact inter-fibrillar spacing and organisation during matrix assembly.(40)  
 
Knock-out mice models have demonstrated the important instructive roles of proteoglycans in 
fibrillogenesis and matrix assembly. Unfavourable structural alterations of the collagen fibrils are 
observed in mice deficient in one or two of the predominant SLRPs (biglycan, decorin, fibromodulin 
or lumican); this frequently results in impaired connective tissue function.(42,43,199,239,290)  
 
 
  Chapter 1





Figure 1.10: A schematic diagram representing the association of aggrecan and the small leucine-rich 
proteoglycans (SLRPs) biglycan, decorin, fibromodulin and lumican, as well as the 
glycosaminoglycans (GAGs), with the collagen network.  
 
 
Murine tissues and mice that lack SLRPs such as biglycan, decorin, fibromodulin, and lumican, have 
similar physical phenotypes to humans with classic EDS.(41-43) EDS is a genetic disorder found in 
humans, the classic form of which is caused by the disruption of the production of type V collagen. 
Similarities between humans with EDS and SLRP knockout tissues include abnormal morphology of 
the collagen fibrils which results in loss of mechanical strength, joint laxity and skin fragility.(41,43,199) 
Mice deficient in the biglycan gene have connective tissue disorders including collagen fibril 
abnormalities in skin, tendon and bone, OA, low bone mass and ectopic tendon ossification.(41,42,293) 
Decorin knockout mice (decorin deficient) display collagen fibrils with highly irregular 
shapes/diameters and abnormal fibrillar organization that is loosely packed due to abnormal lateral 
fusion.(43) This disruption can lead to pathology. The decorin knockout mice also show decreased skin 
and tendon tensile strength due to the abnormal morphology of the fibrils, which results in loss of 
mechanical strength and the reduction of collagen bound proteoglycans.(43,197,294) This demonstrates 
the vital role of decorin in regulating collagen fibre formation. In vivo, periodontal ligaments from 
decorin deficient mice have been found to have a 2 fold increase in ligament fibroblasts in 
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comparison to tissues from wild type mice.(295) Decorin deficient mice also show an increased ligation 
of TGF-β to its receptors.(296) Following tendon injury, biglycan deficient mice have impaired initial 
healing while decorin deficient mice show diminished healing later on. Mice deficient in these two 
proteoglycans also have modifications to collagen alignment and fibril structure during injury 
response.(297) 
 
Knockout mice that are fibromodulin deficient have tendons with collagen fibrils of small 
diameters.(200,290) They also have an increase in age dependent OA and degeneracy of the articular 
cartilage.(298) Fibromodulin knock-out mice highlight the importance of this proteoglycan in 
maintaining tissue integrity as these mice have abnormal morphology of the collagen fibrils, which 
results in loss of mechanical strength, joint laxity and skin fragility.(41,43,199) Irregular fibril organisation 
observed in fibromodulin knock-out mice highlights that this proteoglycan is responsible for 
regulating fibril thickness.(290) 
 
Knockout mice that do not have a functioning lumican gene show abnormal connective tissue 
phenotypes that include skin laxity and fragility, highlighting the crucial role of lumican in the 
regulation of collagen fibrillogenesis.(199,275)  
 
The cornea, like ligaments and tendons, is composed of a closely regulated collagen network. Eye 
abnormalities have been genetically related to mutations in SLRPs. Mutations in the human decorin 
gene have been associated with congenital stromal corneal dystrophy (299) due to abnormal 
organisation of the corneal collagen fibrils.(300) Loss of function mutations in either the lumican, 
fibromodulin, PRELP or optican proteoglycan genes have been implicated in myopia.(163,301) Further 
studies have shown that lumican knock-out mice have cloudy corneas due to the disruption of the 
collagen organisation,(275) whereas keratocan deficient mice develop corneal collagen fibrils with 
larger diameters.(302)  
 
An important concept must however be noted, that is overlapping functions between the SLRPs, 
such that one SLRP can compensate for the loss of function of another SLRP. For example, in the 
absence of fibromodulin, lumican is up-regulated,(290) and decorin accumulates in the absence of 
biglycan.(42) Gene target studies have shown that re-expression of lumican in the cornea can rescue 
ocular abnormalities in lumican knock-out, or fibromodulin-lumican double knockout mice.(275,303) 
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One can therefore speculate that this observed biological redundancy in the functions of the SLRPs 
may be reflecting the significant biological role they play in regulating fibrillogenesis and maintaining 
the structural properties of tissues. The SLPRs, like the collagen genes, can therefore be considered 
as candidate genes for genetic association studies. 
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1.7 Proteoglycans in the injured state 
 
Proteoglycans have a critical role in the pathophysiology of basement membrane related diseases 
including diabetes, arteriosclerosis and metastasis.(304) Changes in proteoglycan expression and the 
accumulation of GAGs have also been associated with tendon pathology.(11,14) Increased levels of 
proteoglycans in the ECM of tendinopathic tendons are thought to influence the increased hydration 
and swelling of the tissue observed.(305) Mechanical loading to the deep flexor tendons from the hind 
legs of near-term bovine foetuses leads to an increase in the mRNA expression of aggrecan, versican, 
biglycan and decorin, as well as an increase in TGF-β1 mRNA levels.(306) In these same tendons, the 
addition of TGF-β producing cells leads to an increase in aggrecan and biglycan expression as well as 
a slight increase in α1 collagen production. Expression of decorin was decreased slightly.(306) The 
addition of TGF-β to the tendons induced similar changes to that of mechanical loading. This once 
again highlights the role of proteoglycans, with TGF-β, in regulating ECM remodelling following 
mechanical loading. Another study by Attia et al. (2012) detected increased levels of the 
proteoglycans aggrecan, versican, biglycan and decorin, as well as GAG content in rat supraspinatus 
tendons that were subjected to overuse.(307) This same group also recently associated tendon 
aggrecan and GAG content with the degree of tendon pathology. This suggests that proteoglycans 
and GAGs are potential markers of injury progression.(308) Parkinson et al. (2010) have also shown an 
increased synthesis and loss of proteoglycans from the ECM of abnormal (tendinopathic) tendons in 
comparison to normal controls, highlighting the differential proteoglycan turnover between the 
tissues.(309) 
 
In 2011 Young et al. investigated the ECM content of ruptured ACL tissue.(169) They observed lower 
levels of both small and large proteoglycans as well as GAG content in ruptured human ACL tissue in 
comparison to the non-ruptured controls. It is however unknown whether the low levels of 
proteoglycans altered the composition and structure of the ACL ECM, reducing the ability to 
withstand a load and thus causing the injury, or whether the changes in proteoglycans occurred 
after and are a result of the injury.(169) Turunen et al. (2013) also recently observed reduced 
proteoglycan content in the cartilage of ACL transected rabbit knee joints.(310) 
 
Aggrecan has been found to increase in the joint fluid of canines following an ACL injury by unilateral 
surgical transection.(311) It thus appears as though aggrecan is lost from the ACL tissue (169) to the joint 
fluid following an injury. A significant increase in aggrecan was seen in the joint fluid of canines three 
and twelve weeks after transection surgery.(311) Nelson et al. (2006) have also shown that one year 
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after ACL injury, GAG content, of which the majority is assumed to be aggrecan, is significantly 
increased in the femoral articular cartilage of humans. After one year, proteoglycan content is still 
increased but not significantly.(182) This is in line with previous studies by Lohmander et al. (1991, 
1999) which showed an increase of aggrecan in the joint fluid following injury.(312,313) The same study 
by Nelson et al. (2006) identified a direct correlation between proteoglycan/GAG content and total 
collagen content of cartilage tissue.(182) 
 
Increased synthesis and accumulation of biglycan in the ECM is phenotypic of fibrotic conditions,(314-
316) including hypertrophic scar (317) and atherosclerotic plaque formation.(318) There are contrasting 
results regarding biglycans expression within the ACL following an injury. Lo et al. (1998, 2003) 
revealed that injured/disrupted ACLs express higher quantities of biglycan, and levels remain 
elevated for longer than one year after injury,(319,320) whereas Young et al. (2011) reported lower 
levels of biglycan in ruptured ACL tissue in comparison to control tissue.(169)  
 
Provenzano et al. (2005) have previously shown an increase in mRNA expression of decorin and 
fibromodulin seven days after a ligament sprain injury.(321) Unchanged levels of decorin have 
however also been observed in the comparison of ruptured and non-ruptured ACL samples.(169) 
Decorin does however seem to be more complicated because the core protein bound by GAGs 
increases inflammatory signalling,(264) whereas the core protein alone is anti-inflammatory.(322)  
 
Although the knowledge of the role of proteoglycans in ACL ruptures is limited, the above literature 
review provides reasonable evidence to choose the genes encoding proteoglycans as candidates to 
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As discussed in the previous chapter, although the aetiology of the molecular mechanisms is poorly 
understood, multiple intrinsic and extrinsic risk factors, including genetics, have been associated with 
ACL ruptures (Chapter 1, Section 1.3).(9,34-39) Polymorphisms within several genes encoding collagens, 
implicated in the regulation of fibrillogenesis, have been associated with ACL ruptures (Section 
1.3.2).(35-38) Similar to the collagens, the proteoglycans aggrecan, biglycan, decorin, fibromodulin and 
lumican have important structural roles in ligaments and also play an essential role in regulating 
fibrillogenesis (Section 1.6).(40) 
 
Mutations within the large ACAN gene cause either dominant familial osteochondritis dissecans, or a 
recessive skeletal dysplasia in humans.(159,160) Murine tissues and mice deficient in the SLRPs biglycan, 
decorin, fibromodulin, or lumican, have similar physical phenotypes to humans with classic EDS: 
fibrillogenesis is compromised resulting in collagen fibrils of highly irregular diameters and abnormal 
fibrillar organisation.(41-43) Young et al. (2011) recently investigated the ECM content of ruptured ACL 
tissue. Lower proteoglycan and GAG levels were observed in ruptured human ACL tissue in 
comparison to the non-ruptured controls.(169) Genes encoding proteoglycans are therefore plausible 
candidate genes to be investigated for an association with ACL injury risk.  
 
Variants within the ACAN and LUM genes, on chromosomes 15q26.1 and 12q21.3 respectively, have 
previously been associated with several multifactorial conditions.(231-234,285,286) The genes encoding 
BGN on chromosome Xq28, DCN on chromosome 12q21.33, and FMOD on chromosome 1q32, have 
however not been associated with any multifactorial conditions to date. 
 
This chapter aimed to investigate the association of polymorphisms in the ACAN, BGN, DCN, FMOD 
and LUM candidate genes with ACL ruptures, and specifically non-contact ACL ruptures, based on the 
important biological functions of these five proteoglycan encoding genes in maintaining the 
structural integrity of tissues and regulation of fibrillogenesis. More importantly, the study aimed to 
identify genomic regions encompassing these five genes which may be harbouring DNA sequence 
signatures relevant to our understanding of ACL injury susceptibility. In addition, we aimed to 
investigate if there was any contribution of these variants to sex-linked susceptibility, as has been 
previously noted with ACL ruptures.(37,38) 
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2.2 Materials and Methods 
 
The reporting of this case-control genetic association study is in alignment with the 
recommendations outlined by the STREGA (STrengthening the REporting of Genetic Association 
studies) initiative, which is an extension of the STROBE (STrengthening the Reporting of 
OBservational Studies in Epidemiology) statement.(323) 
 
 
 2.2.1 Participants 
 
A total of 461 physically active, unrelated, self-reported Caucasian participants were recruited for 
this case-control genetic association study. These participants consisted of 227 (166 male) 
participants with surgically diagnosed ACL ruptures (ACL group) recruited from the Sports Science 
Orthopaedic Clinic in Cape Town, South Africa, and 234 (144 male) apparently healthy participants, 
without any history of ACL injuries (CON group) that were recruited as controls from sports clubs and 
wellness centres within Cape Town, South Africa. Recruitment of participants took place between the 
years of 2006 and 2013. Previously described inclusion and exclusion criteria were used.(37) 
 
All participants were given information about the study (Appendix A) and were required to complete 
a written informed consent form according to the declaration of Helsinki (Appendix A). Participants 
were also requested to complete a questionnaire regarding personal details, medical history, 
personal and family ligament and tendon injury history, as well as sports participation (Appendix A). 
All participants were of self-reported Caucasian ancestry. 
 
Participants within the ACL group could be classified into subgroups by mechanism of injury 
according to the American Orthopaedic Society for Medicine classification system.(324) These 
subgroups were direct contact, indirect contact, non-contact, skiing accident or trauma (for example 
motor vehicle accident). There was insufficient evidence to identify the exact mechanism of injury of 
22 participants (9.69%, 16 male). The most common mechanism of ACL injury was non-contact 
(NON). This subgroup consisted of 126 participants (61.46%, 94 male) that were analysed as part of 
the ACL group and underwent additional statistical evaluation separately.  
 
Sports participation of the CON and ACL groups was characterised into contact sports, non-contact 
jumping sports, non-contact non-jumping sports and skiing sports as previously defined,(9) with slight 
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modification.(37) The most common sports played by the ACL group males were rugby (45.2%) and 
soccer (8.4%), whilst the ACL group females played predominantly hockey (26.2%) and netball 
(14.8%). 
 
This study was approved by the Research Ethics Committee of the Faculty of Health Sciences within 
the University of Cape Town, South Africa (reference number 164/2006) (Appendix B). 
 
 
 2.2.2 DNA extraction 
 
Approximately 5ml of venous blood was obtained from each participant by venepuncture of a 
forearm vein and collected into an ethylenediaminetetraacetic acid (EDTA) vacuum container tube. 
Blood samples were stored at -20˚C until total DNA extraction was performed as previously described 
by Lahiri and Nurnberger (1991),(325) and modified by Mokone et al. (2005).(326) (Appendix C) 
 
 
 2.2.3 Single nucleotide polymorphism selection and Genotyping 
 
SNPs within each of the five candidate genes were identified using the genome database hosted by 
the National Centre for Biotechnology Information (NCBI) (http://ncbi.nlm.nih.gov/) as well as 
SeattleSNPs (http://pga.gs. washington. edu/). SNPs were selected based on previous associations, 
whether they were Tag SNPs and should thus provide moderate coverage of the genetic 
interval,(270,271) or if the SNP had a heterozygosity score greater than 30%. 
 
Three SNPs were investigated in ACAN (Figure 1.5) and included: (i) rs2351491 23 C>T, previously 
associated with height in individuals of African ancestry,(232) (ii) rs1042631 4157 T>C and (iii) 
rs1516797 -1133 T>G, with the latter two SNPs being previously associated with lumbar disc 
degeneration.(233) The two SNPs investigated within BGN (Figure 1.6) included rs1126499 189 C>T and 
rs1042103 359 G>A, both of which were previously investigated for an association with congenital 
muscular dystrophy but excluded as a cause of the disorder.(327) DCN rs13312816 IVS1 A>T and 
rs516115 IVS3 A>G, are both Tag SNPs (270,271) and should therefore provide a large coverage of the 
genomic region spanning approximately 18 Kb of the DCN gene (Figure 1.7). Rs7543148 244 G>A, 
with a heterozygosity score greater than 30%, and rs10800912 -1338 C>T, a Tag SNP, were chosen for 
investigation within the FMOD gene. LUM rs2268578 697 T>C, a Tag SNP,(271,272) has previously been 
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associated with multifactorial phenotypes.(271,287) Schematic diagrams of the FMOD and LUM genes 
are given in Figure 1.8 and Figure 1.9 respectively. Nomenclature used to describe the SNPs 
investigated is in accordance with the NCBI (http://ncbi.nlm.nih.gov/). 
 
TaqMan® allele-discrimination assays (Applied Biosystems, Foster City, California, USA) were used to 
genotype participants for the ten SNPs. Previously inventoried TaqMan® primer sets and allele 
specific MGB-labelled probes were used together with the PCR master mix, containing ampliTaq® 
DNA polymerase Gold (Applied Biosystems, Foster City, California, USA), as per manufacturers 
recommendations in a final reaction volume of 8µl. The PCR reactions were performed on an Applied 
Biosystems StepOnePlus™ Real-Time PCR system (Applied Biosystems, Foster City, California, USA) 
using the Applied Biosystems Step-OnePlus™ Real-Time PCR software Version 2.2.2 (Applied 
Biosystems, Foster City, California, USA). The PCR parameters comprised a 30 second hold step at 
60˚C followed by a 10 minute heat activation step at 95˚C, 40 cycles of 95˚C for 15 seconds and 60˚C 
for 1 minute, ending with a 30 second hold step at 60˚C. Genotypes were determined by endpoint 
fluorescence. For PCR and genotype quality control purposes, a number of positive (known 
genotypes) and DNA-free controls were randomly included on every 96-welled PCR plate. The DNA 
free controls were successful 100% of the time and the positive controls were successful 99.3% of 
the time. The genotypes of each of the samples were checked by an independent person to 
guarantee accuracy.  
 
All laboratory work, DNA extraction and sample genotyping, took place at the UCT/MRC Research 
Unit for Exercise Science & Sports Medicine Laboratory, Faculty of Health Sciences, University of 
Cape Town. Asanda Mtintsilana is acknowledged for the genotyping, in part, of the SNPs within the 
FMOD and LUM genes. 
 
 
 2.2.4 Statistics  
 
Quanto Version 1.2 (http://hydra.usc.edu/gxe) was used to determine the statistical power of the 
sample size. Assuming allele frequencies between 0.1 and 0.9 for the “risk” allele of each SNP 
investigated, our sample size of 227 cases would be adequate to detect an allelic odds ratio of 1.8 
and greater, at a power of 80% and a significance level of 5%. 
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Genotype and allele frequencies were analysed using Statistica Version 11 (StatSoft Inc, Tulsa, 
Oklahoma, USA) and GraphPad InStat Version 5 (GraphPad software, San Diego, California, USA). The 
BGN gene is on the X chromosome and therefore genotype and allele frequencies of SNPs 
investigated in this gene were compared separately between male and female participants. One-way 
analysis of variance (ANOVA) was used to compare continuous biological characteristics between the 
CON and ACL groups and between the CON group and NON subgroup. Chi-squared and Fisher exact 
tests were used to compare categorical variables (sex and country of birth) between the CON group, 
ACL group and NON subgroup, as well as to analyse any differences in genotype and allele 
frequencies between the groups. A Fisher Exact test was used to compare variables between groups 
when n<10 for one of the groups, and a Chi-squared test was used when n>10 for both of the groups 
being examined. Inferred haplotypes were constructed for the ACAN, BGN, DCN and FMOD genes 
using the specific SNPs investigated within each gene. A haplotype was also constructed to overlap 
the LUM-DCN genetic interval (12q21.3-12q21.33) using the SNPs investigated within these genes. 
The Chaplin case-control haplotype inference software program Version 1.2.2 
(http://www.genetics.emory.edu/labs/epstein/software/chaplin/index.html) was used to compare 
allele frequencies of the variants within each haplotype between cases and controls. CubeX: cubic 
exact solution (http://www.oege.org/software/cubex/)(328) was used to determine which of the SNPs 
investigated are in LD and thus likely to be inherited together. Significance was accepted at p<0.05. In 
order to determine whether the genotypes obtained for each of the SNPs investigated were in 
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 2.3.1 Participant characteristics 
 
There were significantly more males in the ACL group (p=0.008) and NON (p=0.013) subgroup in 
comparison to the CON group (Table 2.1). Participants within the CON group, ACL group, and NON 
subgroup, were similarly matched for critical BMI (BMI at recruitment for CON group) (p=0.107 and 
p=0.141 respectively) and country of birth (COB) (p=0.769 and p=0.814 respectively). The ACL group 
(p=0.019) and NON subgroup (p=0.028) were significantly younger than the CON group. When co-
varied for the differences in sex and age, the ACL group (p=0.002) and NON subgroup (p=0.011) still 
weighed significantly more than the CON group. When co-varied for sex, height did not differ 
significantly between groups (p=0.231 and p=0.153 respectively). 
 
 
Table 2.1: Characteristics of the asymptomatic control group (CON), the ACL rupture group (ACL), 
and the ACL subgroup with a non-contact (NON) mechanism of injury. 
 
 
Data reported as mean ± standard deviation, except for sex and COB which are presented as 
frequency (%). 
The number of subjects with available data for each variable is reported in parentheses. 
† CON vs ACL 
‡ CON vs NON 
Age, weight and BMI are self-reported values at the time of first ACL rupture for the ACL group and 
the NON subgroup, and at time of recruitment for the CON group. 
Un-adjusted p values are shown, with the exception of weight and height which have adjusted p 
values in parentheses. Weight has been adjusted for age and sex, and height has been adjusted for 
sex only.  
Significant p values are noted in bold. 
Abbreviations: BMI, body mass index; COB, country of birth; SA, South African. 
 
CON (n = 234) ACL (n = 227) p Value † NON (n = 126) p Value ‡ 
Sex, % males 61.5 (234) 73.1 (227) 0.008 74.6 (126) 0.013 
Age, years 29.3 ± 11.3 (228) 26.8 ± 11.0 (198) 0.019 26.6 ± 10.5 (120) 0.028 
Weight, kg 74.0 ± 14.7 (229) 80.2 ± 16.9 (206) <0.001 (0.002) 79.8 ± 15.8 (123) <0.001 (0.011) 
Height, cm 175.0 ± 9.4 (228) 177.5 ± 9.3 (206) 0.006 (0.231) 178.0 ± 9.1 (122) 0.004 (0.153) 
BMI, kg/cm2 23.8 ± 4.1 (228) 24.6 ± 5.8 (206) 0.107 24.6 ± 5.4 (122) 0.141 
COB, % SA 86.2 (225) 82.7 (208) 0.769 82.9 (123) 0.814 
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Age and weight at the time of recruitment of the ACL group was 4.6 ± 8.9 years (n=225) older and 2.0 
± 12.1 kg (n=221) heavier than at the time of the first ACL rupture. In the NON subgroup, the age and 
weight at time of recruitment was 4.1 ± 7.3 years (n=126) older and 2.5 ± 11.0 kg (n=124) heavier 
than at the time of first ACL rupture. 
 
The female ACL and CON groups were matched for participation in non-contact non-jumping sports 
(p=0.764) and skiing sports (p=0.526) (data not shown). The male ACL and CON groups were matched 
for non-contact non-jumping sports (p=0.138). Significantly more participants (male and female) 
within the ACL group, participated in contact sports (p=0.009 and p=0.001 respectively) and non-
contact jumping sports (p=0.003 and p<0.001 respectively) in comparison to the control participants. 
In addition, significantly more participants within the ACL group participated in skiing sports in 
comparison to the male controls (p<0.001). 
 
With the exception of a significant ACAN rs1042631 genotype effect on sex (p=0.033), there were no 
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 2.3.2 ACAN gene 
 
There were no significant differences in the genotype (Figures 2.1A and 2.1B) and allele (Appendix D, 
Supplementary Table 2) frequency distributions between the CON and ACL groups for the ACAN 
rs2351491 (p=0.547 and p=0.415) and rs1042631 (p=0.168 and p=0.064) SNPs. Similar results were 
noted when stratified by mechanism of injury (NON subgroup) and sex (Appendix D, Supplementary 
Table 2). There was a trend (p=0.059) for the TT genotype to be over-represented in the CON group 
(51.1%, n=119) when compared to the ACL group (42.3%, n=96) for rs1516797. Interestingly, the G 
allele of rs1516797 was significantly under-represented in the CON group (27.5%, n=128) (p=0.024; 
OR=0.72; 95% CI:0.55-0.96) in comparison to the ACL group (34.4%, n=156) (Appendix D, 
Supplementary Table 2). No significant differences (p=0.325) in the allele frequencies for rs1516797 
were however noted between the CON and NON groups. The genotype and allele frequency 
distributions for all three SNPs were similar between the male and female participants for all groups 
(CON, ACL and NON). All the groups were in HWE for all three ACAN SNPs (Appendix D, 
Supplementary Table 2). 
 
Only six of the possible eight haplotypes constructed from the three ACAN variants (rs2351491 C>T - 
rs1042631 T>C - rs1516797 T>G) had a frequency greater than 2%. The haplotype containing alleles 
T-C-T was significantly over-represented (p=0.001; LR=10.30) in the CON group (N=233, 43.55%) in 
comparison to the ACL group (N=225, 32.74%), while T-C-G was significantly under-represented 
(p=0.005; LR=7.79) in the CON group (N=233, 20.83%) in comparison to the ACL group (N=225, 
29.08%) (Figure 2.1D). ACAN rs2351491 and rs1042631 were found to be in complete LD (D’ = 1.0), 
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Figure 2.1: A-C: Genotype frequency distribution of ACAN rs2351491, rs1042631 and rs1516797 for 
the control (CON, white bars), anterior cruciate ligament rupture (ACL, black bars) and non-contact 
anterior cruciate ligament rupture (NON, grey bars) groups. D: Frequency distribution of the ACAN 
(rs2351491 C>T - rs1042631 T>C - rs1516797 T>G) inferred haplotypes amongst the control (CON, 
white bars) and anterior cruciate ligament rupture (ACL, black bars) groups. The p values of 
significantly different distributions are noted. The total number of participants with available 
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 2.3.3 BGN gene 
 
There were no significant differences in the genotype frequency distributions between the CON and 
ACL groups, or between the CON group and NON subgroup at the BGN rs1126499 or rs1042103 loci 
for either males (rs1126499: CON vs ACL, p=0.533; CON vs NON, p=0.672; rs1042103: CON vs. ACL, 
p=0.383; CON vs. NON, p=0.580) or females (rs1126499: CON vs ACL, p=0.105; CON vs NON, p=0.278; 
rs1042103: CON vs. ACL, p=0.226; CON vs. NON, p=0.584) (Figure 2.2A-D). Similarly, no significant 
differences in allele frequencies were noted (Appendix D, Supplementary Table 2). However, there 
was a trend for the BGN rs1126499 T allele to be under-represented (p=0.068) in the female CON 
group (48.3%, n=85) when compared to the female ACL group (59.0%, n=72). All the female groups 
were in HWE for both BGN SNPs. 
 
There were no significant differences in the distribution of the inferred haplotypes constructed from 
the BGN variants (rs1126499 C>T - rs1042103 G>A) when only the male participants were compared 
between the CON and ACL groups (Figure 2.2E). However, when the female participants were 
compared, the BGN C-G inferred haplotype was significantly over-represented (p=0.027) in the CON 
group (N=88, 39.64%) in comparison to the ACL group (N=61, 27.15%) (Figure 2.2F). BGN rs1126499 
and rs1042103 were found to be in low LD (D’=0.321). 
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Figure 2.2: A-D: Genotype frequency distribution of BGN rs1126499 and rs1042103 for the control 
(CON, white bars), anterior cruciate ligament rupture (ACL, black bars) and non-contact anterior 
cruciate ligament rupture (NON, grey bars) groups for male and female participants. E-F: Frequency 
distribution of the BGN (rs1126499 C>T - rs1042103 G>A) inferred haplotypes amongst the control 
(CON, white bars) and anterior cruciate ligament rupture (ACL, black bars) groups for male and 
female participants. The p values of significantly different distributions are noted. The total number 
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 2.3.4 DCN gene 
 
No significant differences in genotype frequencies were noted for the DCN rs13312816 (p=0.221) or 
rs516115 (p=0.926) SNPs when all participants (male and female) were analysed, or when only the 
male participants (rs13312816: p=0.256; rs516115: p=0.334) were analysed between the groups 
(Figure 2.3A and 2.3C); similarly, no significant differences in allele frequencies were noted (Appendix 
D, Supplementary Table 2). Furthermore, no significant difference in the genotype distribution of 
DCN rs13312816 was noted in females (p=0.214) (Figure 2.3B). However, the GG genotype of 
rs516115 was significantly over-represented in the CON group (13.3%, p=0.015; OR=9.23; 95% 
CI:1.17–73.01) when compared to the ACL group (1.6%), as well as being significantly over-
represented in the CON group (13.3%, p=0.035; OR=10.35; 95% CI:0.60–180.20) in comparison to the 
NON subgroup (0.0%), where the GG genotype was absent when only female participants were 
compared. In contrast, the AA genotype was under-represented in the CON group (38.9%, p=0.065) 
in comparison to the ACL group (54.2%) and significantly under-represented in the CON group 
(38.9%, p=0.013; OR=0.33; 95% CI:0.14-0.78) compared to the NON subgroup (65.6%) when only 
female participants were analysed (Figure 2.3D). In addition, the G allele of rs516115 was 
significantly over-represented in the CON group (37.2%) when compared to the ACL group (23.8%, 
p=0.014; OR=1.90; 95% CI:1.14–3.18) and the NON subgroup (17.2%, p=0.003; OR=2.86; 95% 
CI:1.40–5.85) when only female participants were analysed (Appendix D, Supplementary Table 2). 
There were no significant differences in the allele frequency distributions of rs13312816 between the 
three groups for the female participants. All the DCN variants were in HWE for all groups. 
 
Only three of the possible four inferred haplotypes constructed for the two DCN variants 
(rs13312816 A>T - rs516115 A>G) had a frequency greater than 0%. There were no significant 
differences in the distribution of the DCN inferred haplotypes when only male participants were 
compared between the CON and ACL groups (Figure 2.3E). When the female participants were 
analysed, there was a trend for the T-A haplotype to be under-represented in the CON group (N=90, 
62.8%) in comparison to the ACL group (N=61, 76.2%) (Figure 2.3F). DCN rs13312816 and rs516115 
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Figure 2.3: A-D: Genotype frequency distribution of DCN rs13312816 and rs516115 for the control 
(CON, white bars), anterior cruciate ligament rupture (ACL, black bars) and non-contact anterior 
cruciate ligament rupture (NON, grey bars) groups for male and female participants. E-F: The allele 
frequency distribution of the DCN (rs13312816 A>T - rs516115 A>G) inferred haplotypes amongst the 
control (CON, grey bars) and anterior cruciate ligament rupture (ACL, black bars) groups for male and 
female participants. The p values of the significantly different haplotypes are indicated. The total 
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 2.3.5 FMOD and LUM genes 
 
No significant differences in genotype frequencies were noted between the CON and ACL groups 
when the variants in the FMOD (rs7543148: p=0.458; rs10800912: p=0.616) (Figures 2.4A and 2.4B) 
and LUM (rs2268578: p=0.598) (Figure 2.4C) genes were analysed. Similarly, no significant 
differences in allele frequencies were noted between these groups (Appendix D, Supplementary 
Table 2). Likewise, no significant differences in the genotype and allele frequency distributions were 
noted when data was stratified by mechanism of injury or sex. 
 
There were no significant differences in the distribution of the inferred haplotypes for FMOD 
(rs7543148 G>A – rs10800912 C>T) between CON and ACL groups (data not shown). Only six of the 
possible eight haplotypes constructed for the 56 Kb genetic interval overlapping the LUM and DCN 
genes (rs2268578 T>C - rs13312816 A>T - rs516115 A>G) had a frequency greater than 2%. The T-A-G 
inferred haplotype was significantly over-represented (p=0.038) in the CON group (N=234, 9.16%) in 
comparison to the ACL group (N=227, 7.26%) (Figure 2.4D). LUM rs2268578 and DCN rs13312816 
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Figure 2.4: A-B: Genotype frequency distribution of FMOD rs7543148 and rs10800912 for the 
control (CON, white bars), anterior cruciate ligament rupture (ACL, black bars) and non-contact 
anterior cruciate ligament rupture (NON, grey bars) groups. C: Genotype frequency distribution of 
LUM rs2268578 for the control (CON, white bars), anterior cruciate ligament rupture (ACL, black 
bars) and non-contact anterior cruciate ligament rupture (NON, grey bars) groups. D: The frequency 
distribution of the inferred haplotypes constructed for the genetic interval spanning the LUM and 
DCN genes (rs2268578 T>C - rs13312816 A>T - rs516115 A>G) for the control (CON, grey bars) and 
anterior cruciate ligament rupture (ACL, black bars) groups. The p values of the significantly different 
distributions are indicated. The total number of participants with available genotype data within 
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Proteoglycans, such as aggrecan, have major structural roles in ligaments, and the SLRPs biglycan, 
decorin, fibromodulin and lumican are critical in regulating both ECM remodelling and collagen 
fibrillogenesis through their interactions with the collagen fibril, the major building block of ligaments 
and tendons.(195,252,258) In light of the essential role of proteoglycans in fibrillogenesis, and the 
previous associations of sequence variants within genes implicated in fibrillogenesis (COL1A1, 
COL5A1 and COL12A1) with ACL injury risk,(35-38) this study aimed to investigate ten variants within 
five genes encoding proteoglycans (ACAN rs2351491, rs1042631, rs1516797, BGN rs1126499, 
rs1042103, DCN rs13312816, rs516115, FMOD rs7543148, rs10800912, and LUM rs2268578) for an 
association with the risk of ACL injuries. The main findings of this study include: (i) ACAN rs1516797 
was independently associated with the risk of ACL injury in all participants; (ii) DCN rs516115 was 
independently associated with the risk of injury in female participants (sex-linked association); and 
(iii) inferred haplotype analyses further implicated regions overlapping four of the proteoglycan 
encoding genes (ACAN, BGN, and LUM-DCN) with ACL injury susceptibility. This study is the first 
report of genetic associations between the genes encoding proteoglycans and ACL injury 
susceptibility. 
 
Aggrecan is a large, structural proteoglycan that associates with the collagen network, maintaining 
the structure of ligaments by attracting water (Figure 1.10). It is composed of a protein core 
(approximately 230kDa) comprising three globular domains.(329-331) The present study found that 
participants with the rs1516797 G allele had an increased risk of rupturing their ACL (p=0.024; 
OR=0.72; 95% CI:0.55-0.96). Although the genotype frequency distribution was not significantly 
different between the ACL and CON groups, the trend suggests that the G allele may be associated 
with increased ACL injury susceptibility, while the TT genotype appears to be protective. The 
biological function of this T>G substitution in intron 12 of ACAN is unknown. The significant genotype 
effect of ACAN rs1042631 on sex (p=0.033) (Appendix D, Supplementary Table 1) noted in this study 
may be explained by the observation that the TT genotype of rs1042631 is rare among the 
participants (2.39%); only 11 males (3.55%) and 6 females (4.00%) in the study group have the TT 
genotype. This is in agreement with the reported TT genotype frequency of 1.8% within the general 
Caucasian population according to the HapMap-CEU 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1042631). The authors are not aware of 
any plausible biological explanation for this observed genotype effect association. The significance of 
these observed frequencies needs to be further explored in larger sample sizes. 
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Analysis of ACAN inferred haplotypes (rs2351491 C>T - rs1042631 T>C - rs1516797 T>G) further 
highlights the potential role of aggrecan in the pathobiology of ACL injury susceptibility. The T-C-G 
haplotype was associated with an increased risk of ACL ruptures (p=0.005) while the T-C-T haplotype 
was associated with a decreased risk of ACL ruptures (p=0.001). These inferred haplotypes, which 
overlap the G3 domain, are therefore suggesting that this genomic interval, including ACAN 
rs1516797 T>G, may be harbouring DNA sequence signatures which may possibly modify aggrecans 
interaction with the collagen fibril, and this DNA region should thus be further explored. 
Interestingly, disease-causing mutations in proximity to rs1516797 T>G have been associated with 
inherited forms of skeletal dysplasia, a connective tissue disorder.(159,160)  
 
This study also provided preliminary evidence suggesting that SLRPs such as biglycan and decorin 
may play a role in the pathobiology of ACL injuries. Disease-causing mutations within the DCN gene 
have previously been associated with connective tissue disorders.(300,332) The SLRPs function 
predominantly in collagen fibrillogenesis, but have also been implicated in regulating cell growth and 
matrix remodelling.(163,189,195,197,199,252) 
 
BGN was chosen as a candidate for investigation because it is on the X chromosome; sex is an 
intrinsic risk factor for ACL ruptures (107) and previous ACL injury genetic association studies have 
observed sex-genetic interactions.(37,38) Although neither of the two SNPs investigated within the BGN 
gene were independently associated with ACL injury risk, the C-G BGN inferred haplotype (rs1126499 
C>T – rs1042103 G>A) was associated with a decreased risk of ACL injury in females (p=0.027). This 
haplotype analysis suggests that the region overlapping BGN may be modulating ACL injury 
susceptibility and more specifically, this genomic interval in the BGN gene should be further explored 
to identify the causal regulatory DNA sequence signatures. 
 
Biglycan regulates collagen fibrillogenesis and structure by interacting with collagen fibrils (Figure 
1.10).(195) In addition, biglycan also interacts with growth factors such as TGF-β, indicating this 
proteoglycans involvement in modulating growth factor availability to cells and its role in regulating 
matrix turnover.(189) It is interesting to note that previous genetic association studies have also 
observed a similar sex-specific selective advantage, as identified in this study, with variants localised 
to the COL5A1 3’-UTR which is also implicated in fibrillogenesis.(37)  
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The core protein of DCN, another SLRP investigated, binds to collagen to regulate collagen 
fibrillogenesis (Figure 1.10).(197) This study noted that DCN rs516115 A>G was implicated in ACL injury 
risk in female participants, with the GG genotype specifically associated with a 10.4 fold decreased 
risk of injury (p=0.035; OR=10.35; 95% CI:0.60–180.20) and the AA genotype associated with an 
increased risk of injury (p=0.013; OR=0.33; 95% CI:0.14-0.78) when the CON and NON groups were 
compared. The associations were further illustrated when the A and G alleles were significantly over-
represented in the ACL and CON groups respectively (p=0.014), and mirrored when data was 
stratified by mechanism of injury (p=0.003). The functional significance of this variant is unknown but 
one can hypothesise that variations in the LRR protein core may modify the interaction of decorin 
with TGF-β or the collagen fibril,(252,260) thereby possibly modifying fibrillogenesis and affecting the 
mechanical properties of the ligament. 
 
Although biglycan is on the X chromosome, it is suggested to behave like a pseudo-autosomal gene 
that escapes X-inactivation and has an active copy on the Y chromosome. There is however also 
conflicting evidence illustrating that biglycan does undergo X-inactivation and does not have a Y 
chromosome homologue.(248) The pseudo-autosomal expression of biglycan could be attributed to a 
gene or several genes adjacent to BGN that escape X-inactivation and control the transcriptional 
activity of biglycan.(248) The difference, or lack thereof, in dosage and expression of BGN between 
males and females has not been fully explored, and may play a role in the altered risk of ACL injury in 
females. Ovarian hormone levels, and particularly oestrogen, modulate the synthesis and 
degradation of SLRPs such as biglycan and decorin.(333,334) Receptor sites for oestrogen and 
progesterone have been found in the ACL,(52,119) and sex hormones are suggested to affect ACL 
structure and composition.(119) Therefore it is reasonable to propose that the regulation of SLRPs by 
oestrogen (335-337) may account for the sex-specific association of these proteoglycan genes with the 
risk of ACL injury in females. 
 
Haplotype analysis, the investigation of a set of variants inherited together, is often more 
informative in detecting an association compared to analysing individual variants alone.(225) No 
independent associations were noted for LUM rs2268578, however analysis of the inferred 
haplotype encompassing the LUM and DCN (rs2268578 T>C – DCN rs13312816 A>T - rs516115 A>G) 
genes implicated the T-A-G allele combination with reduced ACL injury risk (p=0.038). This region, 
from rs2268578 to rs516115, spans approximately 56 Kb 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs) encompassing the LUM and DCN genes. 
One can speculate that this genomic interval overlapping LUM and DCN influences ACL injury 
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susceptibility by effecting fibrillogenesis. Therefore it is critical that this genomic region is further 
interrogated to identify functional DNA sequences. Both rs2268578 and rs13312816 (D’=0.927) and 
rs13312816 and rs516115 (D’=1.0) are in LD.  
 
Proteoglycans such as aggrecan, biglycan, decorin, fibromodulin and lumican play an important role 
in fibrillogenesis; possibly through their myriad of interactions with various proteins, including the 
collagens (Figure 1.10), and cell-signalling molecules within the ECM. Altering the properties of the 
collagen fibril will most likely alter both the biomechanical and functional properties of the ligament 
and one can therefore hypothesise that this modulation will impact on ACL injury risk.(140) It was thus 
not surprising that our novel results are implicating sequence variants within four proteoglycan 
genes with ACL injury susceptibility. Although there is no immediate clinical translation from this 
study, the results are suggesting that inter-individual variations in the collagen network and fibril 
assembly might be an important molecular mechanism contributing to the aetiology of ACL ruptures, 
similar to Achilles tendinopathy.(338) To improve our understanding of ACL pathogenesis and 
susceptibility, it is imperative that we start elucidating the net effect of the intricate interactions of 
proteoglycans with their receptors in regulating the structural properties of the ECM, including the 
collagen fibril. The elucidation of these interactions is vital for the development of possible 
therapeutic interventions targeting proteoglycans specifically.(242)  
 
The cases and controls investigated in this study were not matched for the confounding variables 
weight and height, and this is therefore a limitation of the study. Heavier individuals are more likely 
to sustain an ACL rupture as adiposity is a contributing risk factor to the development of 
musculoskeletal soft tissue injuries.(21,33) Although care was taken to recruit controls that participated 
in the same sports as those who had sustained an ACL rupture, a limitation is that the cases and 
controls were not matched exactly for exposure to contact and non-contact jumping sports, which 
are high risk for ACL injuries.  
 
The pathway-based approach followed in this study provides evidence that highlights the potentially 
important biological role that proteoglycans ACAN, BGN, DCN and/or LUM may have in modulating 
ACL injury susceptibility. These findings should however be repeated in independent populations to 
confirm the associations described. These results suggest a need to further interrogate the genomic 
intervals encompassing the proteoglycan genes with regards to ACL injury risk, as well as to identify 
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The novel study presented in Chapter 2 highlights the potential role of proteoglycan genes in the 
modulation of ACL injury risk. ACAN rs1516797 was independently associated with ACL injury risk 
and DCN rs516115 was associated with the risk of ACL ruptures in females only. Furthermore, 
inferred haplotype analyses suggested that genomic regions overlapping ACAN, BGN, DCN and LUM, 
may be biologically important in understanding the mechanisms underlying ACL injury susceptibility. 
The BGN and DCN genes were implicated in the risk of ACL injury in female participants only.  
 
Biglycan and decorin have been implicated in the process of collagen fibrillogenesis through their 
interactions with collagens (Figure 1.10).(195,197) Decorin is known to directly interact with collagen V, 
having either a direct effect on the collagen fibril or affecting the interaction of collagen V with other 
molecules.(256) As described in Chapter 1, (Section 1.3.2.2) rs12722 C>T, the BstUI RFLP within the 
COL5A1 gene, was previously associated with ACL injury risk in a female Caucasian population.(37) 
The CC genotype of COL5A1 rs12722 was found to be significantly over-represented in the control 
group, while the T allele was significantly over-represented in the group with ACL ruptures, when 
only females were investigated in the Caucasian cohort.(37) This Caucasian cohort is the same cohort 
that was analysed for associations between the proteoglycan genes and ACL injury risk in Chapter 2 
of this dissertation, with additions. 
 
The aim of this study was therefore to investigate if there are any gene-gene interactions between 
genes involved in regulating fibrillogenesis, and the modulation of ACL injury susceptibility. The 
objectives were to investigate interactions between the proteoglycan genes implicated in the risk of 
ACL injury in Chapter 2, and the COL5A1 gene previously associated with ACL injury risk.(37) Inferred 
allele constructs were used to investigate the collective interactions between the BGN, DCN and 
COL5A1 risk-associated SNPs, for their possible role in modulating sex-specific ACL injury 
susceptibility. Taking into account the previous findings presented in Chapter 2 and the data 
presented by Posthumus et al. (2009),(37) the hypothesis was that the C allele of rs1126499 C>T and 
the G allele of rs1042103 T>C within BGN, as well as the C allele of COL5A1 rs12722, would be 
associated with a decreased risk of ACL injury. With regards to DCN, the hypothesis was that the A 
allele of rs516115 A>G, together with the T allele of COL5A1 rs12722, would be associated with an 
increased risk of injury, and the alternate alleles (G and C respectively) would be implicated in a 
decreased risk of injury.   
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3.2 Materials and Methods 
 
A total of 461 participants in the previously defined ACL (227 individuals with surgically diagnosed 
ACL ruptures), and CON (234 healthy active individuals without any history of ACL injury) groups, 
were genotyped as part of a previous study (Chapter 2) for SNPs within the BGN (rs1126499 C>T and 
rs1042103 G>A) and DCN (rs516115 A>G) genes. These participants were previously genotyped for 
the rs12722 C>T SNP within the COL5A1 gene by Posthumus et al. (2009).(37) Refer to Chapter 2, 
Section 2.3.1 for details on participant characteristics. 
 
In order to determine whether these genes interact in the modulation of ACL injury risk, inferred 
allele combinations were constructed using the Chaplin case-control haplotype inference software 
program Version 1.2.2 (http://www.genetics.emory.edu/labs/epstein/software/chaplin/index.html). 
The allele constructs included (i) BGN (rs1126499 C>T – rs1042103 G>A) – COL5A1 rs12722 C>T, (ii) 
DCN rs516115 A>G – COL5A1 rs12722 C>T (DCN rs13312816 and rs516115 are in complete LD and 
therefore only one SNP was included), (iii) BGN (rs1126499 C>T – rs1042103 G>A) – DCN rs516115 
A>G and (vi) a combination of all four SNPs within the three genes: BGN (rs1126499 C>T – rs1042103 
G>A) - DCN (rs516115 A>G) - COL5A1 (rs12722 C>T). Allele frequencies of SNPs within each allele 
construct were compared between the ACL group and CON group using the Chaplin software Chi-
squared tests. The NON subgroup defined in Chapter 2 was not analysed for inferred allele 
combinations in this chapter because the sample size became too small to identify valid statistical 
associations. Due to the sex-specific associations identified in Chapter 2, and by Posthumus et al. 
(2009),(37) all analyses were performed on male and female participants separately. 
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 3.3.1 BGN – COL5A1 
 
All of the allele combinations constructed for BGN (rs1126499 C>T – rs1042103 G>A) and COL5A1 
rs12722 C>T had a frequency greater than 2%. There were no significant frequency differences 
between the ACL and CON groups for the inferred allele constructs for BGN (rs1126499 C>T – 
rs1042103 G>A) and COL5A1 rs12722 C>T when only male participants were analysed (Figure 3.1A). 
However, when only the females participants were analysed, the C-G-C allele construct was 
significantly over-represented (p=0.001) in the CON group (N=90, 23.0%) in comparison to the ACL 
group (N=61, 9.7%), and the T-A-T construct was significantly under-represented (p=0.001) in the 
CON group (N=90, 11.3%) in comparison to the ACL group (N=61, 28.4%) (Figure 3.1B).  
 
 
 3.3.2 DCN – COL5A1 
 
All of the allele combinations constructed for DCN rs516115 A>G and COL5A1 rs12722 C>T had a 
frequency greater than 5%. The inferred allele constructs for DCN rs516115 A>G and COL5A1 
rs12722 C>T for male and female participants are displayed in Figures 3.2A and 3.2B respectively. 
The A-T allele construct was significantly over-represented (p=0.027) in the male CON group (N=144, 
41.6%) in comparison to the ACL group (N=166, 36.9%). For the female participants, the A-T 
construct was significantly under-represented (p<0.001) in the CON group (N=90, 30.9%) in 
comparison to the ACL group (N=61, 51.1%), and G-C was significantly over-represented (p<0.001) in 
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Figure 3.1: Frequency distribution of the inferred allele constructs for BGN (rs1126499 C>T – 
rs1042103 G>A) and COL5A1 rs12722 C>T amongst the control (CON, white bars) and anterior 
cruciate ligament rupture (ACL, black bars) groups for male (A) and female (B) participants. The p 
values of significantly different distributions are noted. The total number of participants with 
available genotype data within each group is indicated in parenthesis on the graph. 
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Figure 3.2: Frequency distribution of the inferred allele constructs for DCN rs516115 A>G and 
COL5A1 rs12722 C>T amongst the control (CON, white bars) and anterior cruciate ligament rupture 
(ACL, black bars) groups for male (A) and female (B) participants. The p values of significantly 
different distributions are noted. The total number of participants with available genotype data 
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 3.3.3 BGN – DCN  
 
All of the allele combinations constructed for BGN (rs1126499 C>T – rs1042103 G>A) and DCN 
rs516115 A>G had a frequency greater than 2%. There were no significant differences between the 
ACL and CON groups for the inferred allele constructs for BGN (rs1126499 C>T – rs1042103 G>A) and 
DCN rs516115 A>G when only male participants were analysed (Figure 3.3A). However, when the 
females were analysed, the C-G-G allele construct was significantly over-represented (p=0.011) in 
the CON group (N=87, 13.9%) in comparison to the ACL group (N=57, 7.2%). The T-G-G allele 
construct was also significantly over-represented (p=0.026) in the CON group (N=87, 13.9%) in 
comparison to the ACL group (N=57, 5.7%). In contrast, the T-A-A construct was significantly under-
represented (p=0.021) in the CON group (N=87, 20.2%) in comparison to the ACL group (N=57, 
24.8%) (Figure 3.3B).  
 
 
 3.3.4 BGN – DCN – COL5A1 
 
In order to investigate the potential gene-gene interactions between these three genes (BGN, DCN 
and COL5A1), inferred allele constructs were generated from the genotype data of SNPs within the 
BGN (rs1126499 C>T – rs1042103 G>A), DCN (rs516115 A>G) and COL5A1 (rs12722 C>T) genes. No 
significant differences in the inferred allele constructs were noted between the CON and ACL groups 
when only the male participants were compared (Figure 3.3A).  
 
For the females participants however, the C-G-G-C inferred allele construct was significantly over-
represented (p=0.001) in the CON group (N=90, 10.7%) in comparison to the ACL group (N=61, 
4.2%). C-G-A-C was also significantly over-represented (p=0.044) in the CON group (N=90, 13.3%) in 
comparison to the ACL group (N=61, 3.7%). T-G-A-T on the other hand was significantly under-
represented (p=0.038) in the CON group (N=90, 7.6%) in comparison to the ACL group (N=61, 
10.1%), along with T-A-A-T being significantly under-represented (p<0.001) in the CON group (N=90, 
7.4%) in comparison to the ACL group (N=61, 22.1%) (Figure 3.3B). Inferred allele combinations 
which had frequencies less than 5% in both the ACL and CON groups were not displayed in the 
graphs for Figure 3.3, thus only ten of the possible sixteen allele combinations are presented. 
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Figure 3.3: Frequency distribution of the inferred allele constructs for BGN (rs1126499 C>T – 
rs1042103 G>A) and DCN rs516115 A>G amongst the control (CON, white bars) and anterior cruciate 
ligament rupture (ACL, black bars) groups for male (A) and female (B) participants. The p values of 
significantly different distributions are noted. The total number of participants with available 
genotype data within each group is indicated in parenthesis on the graph. 
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Figure 3.4A: The frequency distribution of the inferred alleles constructs for BGN, DCN and COL5A1 
(rs1126499 C>T – rs1042103 G>A – rs516115 A>G – rs12722 C>T) amongst the control (CON, grey 
bars) and anterior cruciate ligament rupture (ACL, black bars) groups for male participants. The p 
values of the significantly different distributions are indicated. The total number of participants with 
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Figure 3.4B: The frequency distribution of the inferred allele constructs for BGN, DCN and COL5A1 
(rs1126499 C>T – rs1042103 G>A – rs516115 A>G – rs12722 C>T) amongst the control (CON, grey 
bars) and anterior cruciate ligament rupture (ACL, black bars) groups for female participants. The p 
values of the significantly different distributions are indicated. The total number of participants with 
available genotype data within the CON and ACL groups are indicated in parenthesis on the graph. 
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The LUM-DCN haplotype presented in Chapter 2 suggested that gene-gene interactions between 
proteoglycan encoding genes, may be taking place in the modulation of ACL injury risk. The 
investigation of inferred haplotypes or inferred allele combinations is potentially more powerful in 
effectively capturing a risk profile than looking at one polymorphism independently.(339) Independent 
associations with ACL injury risk were noted for sequence variants within (i) proteoglycan genes 
encoding proteins that regulate fibrillogenesis (Chapter 2), and (ii) collagen encoding genes 
(COL5A1)(37) also implicated in fibrillogenesis. Therefore it is reasonable to predict that a model 
comprising both the proteoglycan and collagen associated genes involved in fibrillogenesis, may have 
a greater impact on modulating ACL injury susceptibility. 
 
Biglycan regulates collagen fibrillogenesis and structure by interacting with collagen fibrils.(195) The 
LRRs of the core protein of decorin facilitate its binding to the surface of fibrillar collagens where it 
can retard the rate and degree of collagen fibrillogenesis.(252-255) Type V collagen intercalates with 
type I collagen and is believed to regulate the collagen fibril diameter during fibrillogenesis.(138) The 
binding of decorin to collagen V can have either a direct effect on the collagen itself or may mediate 
the interaction of collagen V with other molecules.(256)  
 
Fibril-collagen interactions are highly important with regards to the ligaments response to loading 
and matrix remodelling (Figure 1.10). Recently it has been hypothesised that sequence variations in 
the collagen encoding genes may alter the structure and assembly of the collagen fibril and therefore 
affect the mechanical properties of the fibril and its response to loading.(140,338) The BGN and COL5A1 
(rs1126499 C>T – rs1042103 G>A - rs12722 C>T) inferred allele construct revealed two alternate 
allele combinations associated with either protection from or risk of injury in female participants. The 
C-G-C allele combination was associated with protection from ACL injury (p=0.001), while T-A-T was 
associated with risk of ACL injury (p=0.001). The inferred allele constructs mimic the observations 
from Chapter 2, where the C-G BGN (rs1126499 – rs1042103) haplotype was associated with a 
decreased risk of ACL injury. This also aligns with the hypothesis and previous findings that the C 
allele of COL5A1 rs12722 is associated with protection from ACL injury and the T allele is associated 
with risk of injury.(37) 
 
The A-T combination of the DCN and COL5A1 (rs516115 A>G - rs12722 C>T) inferred allele construct 
was associated with risk of injury (p<0.001) in females, and the alternate G-C allele construct was 
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associated with protection from injury (p<0.001) in females. Once again, this finding is in line with 
the results of the current and previous studies,(37) highlighting that the A and G alleles of DCN 
rs516115 are associated with risk of and protection from injury respectively (Chapter 2). 
 
When analysing the BGN (rs1126499 C>T – rs1042103 G>A) and DCN rs516115 A>G inferred allele 
construct, two alternate allele combinations were associated with protection from (C-G-G, p=0.011) 
and risk of (T-A-A, p=0.021) ACL injury in female participants only. These combinations are reflective 
of the results observed in Chapter 2 and agree with the hypotheses implicating the respective alleles 
in protection from and risk of ACL injury. A third allele construct (T-G-G) was also associated with 
decreased risk of ACL injury (p=0.026), indicating that the BGN rs1126499 SNP may not have as 
strong of a role in the modulation of ACL injury risk as the other two SNPs investigated in this gene-
gene interaction. 
 
When the SNPs from BGN, DCN and COL5A1 were combined in an inferred allele construct [BGN 
(rs1126499 C>T – rs1042103 G>A), DCN rs516115 A>G and COL5A1 rs12722 C>T], four strong 
associations in line with the above mentioned results were identified. This again echoes the potential 
biological consequence the interactions between the proteoglycan and collagen genes may have in 
collectively modulating the risk of sustaining an ACL rupture. These results emphasise that ACL 
injuries are not only multifactorial, but also that multiple genes may be interacting and contributing 
to the aetiology of this injury.  
 
Similar to the results observed in Chapter 2, female-specific associations were identified in this study. 
The reason for this remains unknown although suggestions have been made. One of these is based 
on the difference, or lack thereof, in the expression of BGN between males and females, because this 
gene is on the X chromosome.(248) Sex hormones are also speculated to affect the structure and 
composition of the ACL,(119) as well as modulate the synthesis and degradation of SLRPs such as 
biglycan and decorin.(333,334) The underlying mechanisms for the observed sex-specific associations 
need to be further explored. 
 
One limitation of the analyses presented in this Chapter was that when participants were stratified 
by sex, and by their specific inferred allele combinations, the sample size was invariably diminished. 
It would be therefore be valuable if the sample size of this study is increased. More importantly, it 
would be beneficial to repeat the study in an independent population. 
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In conclusion, this study revealed evidence suggesting that gene-gene interactions are taking place 
between the proteoglycan genes and the COL5A1 gene in the modulation of ACL injury risk. It is 
likely that multiple genetic variants within genes encoding proteins involved in the regulation of 
fibrillogenesis, ECM structure and remodelling, and multiple gene-gene interactions may affect ones 
susceptibility to sustaining an ACL injury. The interaction of genes within a pathway, such as 
fibrillogenesis (Figure 1.10) and ECM remodelling, is more informative than the independent effect 
of a single gene alone. These results add to the current risk model for ACL injuries. Identifying genes 
implicated in complex multifactorial phenotypes however only partially explains the biological 
pathway that leads to the disease. Only once gene expression, protein function and protein 
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4.1 Summary  
 
ACL ruptures, as highlighted in Chapter 1, are considered one of the most severe and detrimental 
injuries sustained in sports.(30) High risk sports for ACL ruptures, as identified in this study and 
others,(340,341) include rugby and soccer for males, and hockey and netball for females. This is due to 
the fact these are fast moving sports that require rapid stops and changes in direction during play. 
However, ACL injuries are not only contributed to by the sports and activities an individual takes part 
in, it is considered a multifactorial injury caused by multiple risk factors,(21) (Figure 4.1) which can be 
divided into five interacting groups: extrinsic risk factors, and the four intrinsic risk factors, anatomy, 
hormones, neuromuscular activity and genetics.(4,33) Although this dissertation focused on the 
investigation of one of these risks, it is important to understand that the five groups comprise a 



















Figure 4.1: The puzzle pieces of risk factors that contribute to ACL injury susceptibility. Genetic risk 
factors are noted in blue, with the proteoglycan genes (identified in this dissertation) noted in bold. 
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The genetic contribution to ACL injuries, as well as other multifactorial soft tissue injuries, has 
become well-established.(5,21,85,342) Sequence variants within several genes have been implicated in 
the modulation of ACL injury risk, highlighting that this is a polygenic condition which is likely 
contributed to by multiple genes in various pathways. Although proteoglycans are important 
structural components of ligaments, the association of variants within genes encoding proteoglycans 
have not been investigated to date. This dissertation therefore investigated a group of genes, 
encoding proteoglycans, for an association with ACL injury risk.  
 
The aims of this dissertation were: 
 
 to identify novel genetic loci within proteoglycan encoding genes, which may predispose an 
individual to sustaining an ACL rupture, 
 to use inferred haplotype analyses to identify genomic regions within each of the 
proteoglycan genes that may be contributing to ACL injury susceptibility and thus require 
further investigation, 
 to determine whether gene-gene interactions between the proteoglycan genes and the 
previously associated COL5A1 gene may collectively contribute to the modulation of ACL 
injury risk, by exploiting inferred allele constructs. 
 
Proteoglycans form a very important component of the ground substance that comprises the ECM of 
ligaments.(40) They have been implicated in maintaining both the structural and functional integrity 
of tissues by facilitating matrix-matrix interactions, cell-matrix organisation and cell-matrix signalling 
interactions.(158) The genes specifically investigated in this dissertation (ACAN, BGN, DCN, FMOD and 
LUM), encode proteins that interact with the collagen network and regulate fibrillogenesis (Figure 
4.2) and are thus vitally important in ECM homeostasis in the normal state and ECM remodelling 
following mechanical loading.(162) The identification of genes involved in the aetiology of ACL injuries 
will elucidate the significant biological pathways that may be contributing to the mechanisms that 
underlie this injury. Linking genetic variants to injury susceptibility is a tool used to understand gene 
functions (60) and injury development. Only once the mechanisms of injury are understood, can we 
improve prevention strategies to decrease the incidence of injury, as well as to refine treatment and 
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 4.1.1 Novel findings 
 
This dissertation identified the following novel associations: 
 
 ACAN rs1516797 T>G was independently associated with the risk of ACL injury in all 
participants. More specifically, the G allele was associated with a 1.4 fold increased risk of 
ACL rupture (p=0.024). 
 
 DCN rs516115 A>G was independently associated with the risk of injury in female 
participants only (sex-specific association). The GG genotype was associated with a 10.4 fold 
decreased risk of injury (p=0.015) and the AA genotype was associated with a 3 fold 
increased risk of injury (p=0.013) when the CON and NON groups were compared. 
Furthermore, the A and G alleles were significantly over-represented in the ACL and CON 
groups respectively (p=0.014), and mirrored when data was stratified by non-contact 
mechanism of injury (p=0.003). 
 
 Inferred haplotype analyses implicated regions overlapping four of the five investigated 
proteoglycan encoding genes with ACL injury susceptibility.  
 Two ACAN (rs2351491 C>T - rs1042631 T>C - rs1516797 T>G) haplotypes, on 
chromosome 15q26, were associated with risk of injury: the T-C-G haplotype was 
associated with an increased risk of ACL ruptures (p=0.005) while the T-C-T 
haplotype was associated with a decreased risk of ACL ruptures (p=0.001). 
 The C-G BGN (rs1126499 C>T – rs1042103 G>A) haplotype, on chromosome Xq28, 
was associated with a decreased risk of ACL injury in female participants only 
(p=0.027). 
 The haplotype overlapping a 56 Kb region on chromosome 12q21, encompassing 
the LUM and DCN genes [LUM rs2268578 T>C – DCN (rs13312816 A>T - rs516115 
A>G)] was also implicated in ACL injury risk; specifically the T-A-G allele 
combination was associated with a decreased risk of ACL injury (p=0.038).  
 
 Allele constructs revealed that the proteoglycan genes (i) collectively interact with each 
other, and (ii) their interactions with COL5A1 potentially contribute to the modulation of ACL 
injury susceptibility. 
  Chapter 4 
 _________________________________________________________________________________  
81 
  
 The BGN-DCN (rs1126499 C>T - rs1042103 G>A - rs516115 A>G) allele construct 
revealed two alternate combinations that were associated with protection from 
(C-G-G, p=0.011) and risk of (T-A-A, p=0.021) ACL injury in female participants 
only.  
 Two alternate combinations of the BGN - COL5A1 (rs1126499 C>T – rs1042103 
G>A - rs12722 C>T) inferred allele construct, were associated with protection 
from (C-G-C, p=0.001) and risk of (T-A-T, p=0.001) injury in female participants 
specifically.  
 The G-C combination of the DCN - COL5A1 (rs516115 A>G - rs12722 C>T) allele 
construct was associated with protection from injury (p<0.001), while the 
alternate A-T haplotype was associated with risk of injury (p<0.001), both in 
female participants.  
 Four female-specific associations were identified when BGN-DCN-COL5A1 
(rs1126499 C>T - rs1042103 G>A - rs516115 A>G - rs12722 C>T) allele constructs 
were investigated. The C-G-G-C and C-G-A-C constructs were associated with a 
decreased risk (p=0.001 and p=0.044 respectively) of ACL injury in females. While 
T-G-A-T and T-A-A-T were associated with an increased risk of ACL injury (p=0.038 
and p<0.001 respectively) in female participants only. 
 
In summary, two of the ten investigated polymorphisms were independently associated with the risk 
of ACL injury (ACAN rs1516797 and DCN rs516115). Haplotype analyses further implicated regions 
overlapping ACAN, BGN, and LUM-DCN in ACL injury susceptibility. Inferred allele constructs revealed 
that gene-gene interactions between the proteoglycan genes and COL5A1 may collectively modulate 
ACL injury risk. It is important to note that the results of the associated haplotypes and allele 
constructs, were in line with the independently associated polymorphisms and the specific alleles 
were consistently associated with either an increased or decreased risk of ACL injury. This 
dissertation highlights the polygenic nature of ACL injuries and the probability that multiple genetic 
variants within genes involved in the regulation of fibrillogenesis, ECM structure and remodelling, 
and the complex array of gene-gene interactions in response to environmental triggers may together 
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 4.1.2 The biologically significant pathways highlighted in this 
dissertation 
 
Genetic association studies are important tools used to identify genes and biological pathways which 
may contribute to an individual having an inherited predisposition to a multifactorial condition, such 
as an ACL injury. Although one genotype or allele may impact an individual’s susceptibility to injury, 
as was noted with ACAN rs1516797 and DCN rs516115, the combination of several SNPs or genes 
together is likely to have a stronger effect.(343) This dissertation investigated the interaction of genes 
associated with the collagen network, and involved in fibrillogenesis and ECM remodelling; the 
exploration of a pathway is more informative of the mechanisms that may be contributing to injury 
susceptibility than merely examining the independent effect of a single gene.(339) The association of 
sequence variants in the proteoglycan encoding genes can be used as part of a polygenic profile, 
including previously associated SNPs, to identify which individuals have an inherited predisposition to 
ACL injuries. However, it must once again be highlighted that genetics is one piece of the multiple 
risk factors that contribute to the puzzle that is injury (Figure 4.1), and should be used together with 
the other factors in a risk model to determine susceptibility.  
 
The observed net effect of multiple genes and multiple interactions within the collagen network 
(Figure 4.2), as occurs in the regulation of fibrillogenesis, highlights the importance of this process in 
ligament homeostasis and thus provides an additional level of evidence implicating this pathway as 
part of the mechanisms that contribute to injury susceptibility. In the normal, uninjured state, 
ligaments are subjected to small amounts of mechanical loading due to everyday activities.(4) The 
ECM of ligaments is thus continuously undergoing degradation and remodelling in order to maintain 
homeostasis, and fibrillogenesis is an important part of the remodelling process. During this process, 
particular proteins involved, such as the SLRPs and collagens, will have altered expression. It is thus 
reasonable to deduce that if protein expression or function is modified due to variants within the 
respective genes, homeostasis and more importantly fibrillogenesis could be compromised. An 
individual may consequently be at an increased risk of sustaining an ACL injury because the 
biomechanical properties of the ligament will be altered and perhaps even compromised. The exact 
biological implications of each of the proteoglycan genes on the mechanism of injury will however 
remain unknown until the functional role of the polymorphisms and genetic interactions within the 
cells of the ECM are determined.  
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A recent study investigated the binding of decorin to collagen. The highly conserved concave region 
of SLRPs is believed to interact with the collagen triple helices. If mutation sites are engineered at the 
collagen-SLRP interface, it reduces the ability of the SLRP to bind collagen and decorin is 
consequently unable to inhibit collagen fibrillogenesis.(344) Different mutations result in varying 
degrees of binding ability, and it is thus plausible that various genetic polymorphisms, as investigated 
in the studies presented, may affect the binding of SLRPs to collagen and therefore alter the process 
of fibrillogenesis and compromise ligament homeostasis and the ability to effectively resist a load. It 
is therefore reasonable to propose that these genes may harbour potential biologically significant 
polymorphisms which if inherited may modulate an individual’s predisposition to ACL injury. The 
results of this dissertation highlight that the collagen network and fibrillogenesis pathway, and 
possibly the rate and timing of fibrillogenesis as the COL5A1 gene is the rate limiting gene of 
fibrillogenesis,(345) needs to be further explored in order to properly characterise the contribution of 





Figure 4.2: A schematic diagram representing the association of aggrecan and the small leucine-rich 
proteoglycans (SLRPs) biglycan, decorin, fibromodulin and lumican, as well as the glycosaminoglycans 
(GAGs), with the collagen network.  
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 4.1.3 Sex-specific associations 
 
Within this dissertation sex-specific associations were identified for BGN, DCN and COL5A1. The 
reasons for this remain unknown but several suggestions were made. Various intrinsic risk factors 
described in this dissertation are female-specific, such as BMI, ACL size and anatomy, and joint laxity. 
Hormones are believed to greatly influence ACL injury susceptibility (Chapter 1, Section 1.3.1.2), as 
sex hormones modulate the synthesis and degradation of the SLRPs, such as BGN and DCN.(333,334) 
Several other genetic studies investigating ACL injury risk have also observed sex-specific 
associations.(37,38) Oestrogen and progesterone receptor sites have been located in the ACL,(52,119) and 
the sex hormones are suggested to affect ACL structure and composition.(119) The regulation of SLRPs 
by oestrogen (335-337) may be one of the reasons for the sex-specific associations identified in this 
dissertation. For example, the sex hormones may alter the availability of the SLRPs and collagens 
within the ECM. This would therefore effect the ability of these proteins to assist with fibrillogenesis 
during ECM homeostasis and remodelling, thus compromising the integrity of the ligament 
structure, resulting in greater injury susceptibility. The role of sex and sex hormones in ACL injury 
susceptibility is thus another factor that needs to be further investigated in order to determine the 
exact mechanisms that result in females being at a greater risk for ACL injuries.(28,86) 
 
 
In summary, this dissertation successfully used molecular genetics as a tool to identify genes within a 
pathway that may be contributing to the mechanisms that underlie ACL injury risk. It is now apparent 
that the proteoglycan genes and their role in the regulation of fibrillogenesis, may be one of the 
biological mechanisms that if disturbed could result in an individual having a higher probability of 
sustaining an ACL injury. Identifying genes implicated in complex multifactorial phenotypes only 
partially explains the biological pathway that leads to the condition. Only once gene expression, 
protein function and protein interactions are understood will the physiological mechanisms become 
more apparent.(223) Understanding the complex anatomy, function, biomechanics and biology of the 




  Chapter 4 
 _________________________________________________________________________________  
85 
  
4.2 Strengths and limitations 
 
This dissertation, as with any research, has strengths and limitations to the studies presented. 
Although the total sample size of the study was adequate, as determined by Quanto, to detect 
associations with 80% power, it has become clear that because sex is a risk factor for ACL ruptures 
and females are at an increased risk,(28,86) males and females need to be analysed together and 
independently for associations with ACL injuries, to enable the identification of any sex-specific 
genetic loci. This study was not optimally designed to explore sex-specific risk factors and it was 
therefore not surprising that when participants were stratified by sex the sample size, especially for 
the female participants, became underpowered. The percentage of males differed significantly 
between groups and an equal number of males and females therefore need to be recruited for the 
ACL and CON groups in order to more effectively compare the similarities and differences between 
groups.  
 
While effort was made to equally match the CON and ACL participants for the extrinsic risk factors 
they are exposed to, there were differences in sports participation between the groups. Sports 
participation and level of play were well documented, but these were all self-reported and in some 
cases many years after play; it is thus likely that some accounts of sports participation are 
inaccurate. Both the male and female ACL groups had a greater percentage of participants that 
engaged in contact and non-contact jumping sports in comparison to their respective CON groups. 
These types of sports are high risk for the occurrence of ACL ruptures, and it is thus important in the 
future to recruit a greater percentage of controls that participate in these types of sports as well. 
Recruitment therefore needs to be focused at rugby and soccer clubs for males and females, as well 
as netball clubs for females.  
 
Another limitation of this study is in the fact that the weight of participants differed between groups, 
as those with an ACL rupture weighed significantly more than controls, even when adjusted for sex 
and age. Weight is an intrinsic risk for ACL ruptures and a confounding variable because increased 
weight often results in greater knee extension when landing from a jump.(21,33) The weight of 
participants in the ACL group is however recorded as their weight at the time of first ACL rupture 
and this can be inaccurate as some participants are recruited many months or years after the 
occurrence. However this is somewhat out of the control of the investigators, unless the participant 
had seen a doctor soon after the injury and their weight recorded in a patient file which could be 
accessed. Weight and height, and thus BMI, were self-reported values and perhaps exact 
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measurements, including waist circumference, should be taken by investigators to ensure accuracy 
in the future. There were however no genotype effects on weight and BMI detected (Appendix D, 
Supplementary Table 1). 
 
It is acknowledged that this dissertation only investigated a small group of genes and a limited 
number of SNPs that may potentially play a role in ligament homeostasis and the mechanical 
properties of the ligament. It is therefore important that the need to investigate additional loci 
within these genes as well as investigating different genes that may be implicated in the risk of 
sustaining an ACL rupture, is understood. Versican, for example, is another hyalectan proteoglycan 
that should be investigated with regards to ACL injury risk. Alternative splicing of the gene encoding 
versican however yields four different mRNA transcripts,(188,189) which adds a level of complication, 
but our group is currently exploring this. Fibrillogenesis is not the only pathway that may contribute 
to the mechanisms that underlie ACL injuries and various other pathways also need to be explored 
(Section 4.3) in order to fully understand the injury mechanisms, as well as to be able to identify 
individual predisposition to ACL injury.  
 
The great strength to this dissertation is the hypothesis driven approach that was followed. Chapter 
1 presented convincing biological evidence of the significant functions of the candidate genes 
explored in this study with relevance to ligament biology, ECM homeostasis and their potential 
impact on the pathobiological mechanisms underpinning ACL ruptures.  
 
The value of case-control genetic association studies is that they exploit the differences in the 
genetic profile of two extreme phenotypes, being the uninjured (CON) and injured (ACL) 
participants. This case-control genetic association study was also strengthened by the fact that it was 
conducted, and reported in line with the guidelines provided by the STREGA statement.(323) This 
statement provides a checklist to be followed during genetic association studies, adapted from the 
STROBE statement on reporting observational studies. The checklist explicitly describes all rationale 
that should be considered in deciding on study design and provides guidelines for ethical approval, 
recruiting participants and carrying out laboratory work. Finally the statement advises on the 
accurate and unbiased reporting of the results of the research with emphasis on transparency in 
reporting evidence of genetic association studies. This statement was developed by a 
multidisciplinary group of scientists and thus reflects a collaborative approach. Consistent with the 
STREGA laboratory guidelines, multiple control samples were included in the genotyping of 
participants for the various SNPs investigated. On each 96 well PCR plate run, three repeat samples 
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and three DNA free controls were included. The DNA free controls were successful 100% of the time 
and the repeat samples were successful 99.3% of the time, where in one instance a repeat sample 
was uncalled. Lastly, the genotypes of each of the samples were further checked by an independent 
person to guarantee quality control. With regards to genotyping, 99.8% of all samples were 
successfully genotyped for all ten SNPs. All attempts were made to adhere to the strict principles 
and guidelines of the STREGA report for quality control purposes. 
 
However, as with any novel findings, the associations noted in this study should be repeated in 
larger independent populations in order to confirm all the observed results.(346) 
 
  
  Chapter 4 
 _________________________________________________________________________________  
88 
  
4.3 Future prospects 
 
The results of this dissertation provide the initial evidence implicating the genes encoding 
proteoglycans in the risk of ACL injuries. ACAN and DCN were independently associated with ACL 
injury susceptibility, and regions overlapping ACAN, BGN, LUM and DCN were also implicated in the 
risk of injury. Variants within BGN and DCN were found to interact with a variant in COL5A1 in the 
modulation of ACL injury risk. This is however only a first look at polymorphisms, within the 
proteoglycan encoding genes that may be contributing to the mechanisms that underlie individual 
susceptibility to ACL injuries, and the regions that have been implicated in this study need to be 
further explored. We hypothesise that variants within the proteoglycan encoding genes may 
influence protein expression and potentially protein interactions, specifically interactions with the 
collagen network in the modulation of fibrillogenesis. Proteoglycan genes also function as cell 
signalling molecules and therefore variants within the genes may also affect ECM homeostasis and 
turnover, and thus comprise the ability of the ligament to respond to loading, which could lead to 
injury.(162,305) However, in order to understand the mechanisms that lead to injury, and the exact role 
of proteoglycans, further investigation needs to take place. 
 
The first step in further exploring the mechanistic role of proteoglycans in ACL ruptures is to confirm 
the findings observed in an independent population. Associating a variant with ACL injury risk in a 
single population does not prove that the polymorphism is actually associated with the 
pathophysiology of the injury. The confirmation of genetic associations in independent populations 
is required to evaluate the validity of the association or the contribution of a particular gene to the 
risk of the multifactorial condition. Investigating a different population would also potentially assist 
in narrowing the genetic interval of interest that may underlie predisposition to ACL ruptures, 
because LD relationships differ across populations.(346) If the association of a particular variant 
persists in a different population, where the frequency of the variant differs and genomic variation is 
greater, it suggests that the variant may have, or be tightly linked to a variant with a functional role 
in the mechanism of injury. It is thus crucial to repeat this study in an independent Caucasian 
population to provide the findings with credibility,(346) as well as to repeat this investigation in a 
different population of dissimilar ancestry, in order to determine whether the association persists or 
not. The genetic risks for ACL ruptures may differ between population groups and therefore this 
needs to be examined. 
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There are very limited studies investigating genetic variants in non-Caucasian populations, but our 
research group has already begun recruiting individuals of other South African populations, including 
Black and Mixed Ancestry, in order to repeat the genetic associations identified in this study and 
previous.(36-39) African populations have higher levels of genetic variation and diversity in comparison 
to non-African populations, who contain a subset of the genetic diversity seen in Africa.(347,348) The 
high genetic variation observed in African populations could assist in defining the particular genetic 
intervals associated with predisposition to ACL ruptures, and it is thus important to evaluate genetic 
associations in the broader populations of South Africa. The similarities or differences between 
variants in different populations will assist in identifying the relative contribution of each variant to 
the risk of ACL ruptures.  
 
This dissertation implicated several regions overlapping proteoglycan genes in ACL injury 
susceptibility which now need to be narrowed down. Sequencing of the proteoglycan genes can be 
used to identify the important genetic regions responsible for the modulation of ACL injury risk. 
Targeted sequencing using next generation sequencing technology, and several bioinformatics tools 
can be employed to narrow the genetic interval of interest, as well as to identify additional novel 
polymorphisms which may be contributing to ACL injury risk.(349) Genotyping variants identified in 
the target region, in a large cohort, enables you to fine-map the association.(349) Next generation 
sequencing is however an expensive process and thus the confirmation of the genetic associations 
observed and the investigation of the associations in different populations is the first critical step in 
the discovery process.  
 
Once sequencing has been used to verify the genetic interval of interest and subsequent associated 
polymorphisms confirmed, the region should be further scrutinised. Associated variants should be 
subjected to functional studies in order to determine the functional significance of particular 
polymorphic alleles. Reporter assays can be used to determine gene activity and mRNA stability 
when alternate alleles are present.(139,220) Bioinformatic tools can be applied in order to determine 
whether any binding sites are present in the genetic interval that was narrowed down by 
sequencing.(139) Polymorphisms within binding target regions could compromise the interaction of 
the gene with various other molecules, and polymorphisms within proteoglycans in particular could 
alter interactions with the collagen network and negatively affect ligament homeostasis. 
Determining the functional consequences of associated polymorphisms will aid in understanding the 
molecular mechanisms that are responsible for the pathway that leads to an ACL rupture. Exploring 
the interactions and functional relationships between multiple genes will help us to comprehend the 
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biological dynamics of the ligament. This will enable us to become closer to understanding a cause-
effect relationship that could possibly be intervened.(220)  
 
This dissertation investigated the interaction of the proteoglycan genes with COL5A1 (Chapter 3), 
and the possibility that variation in these interactions could modulate ligament fibrillogenesis and 
lead to injury. Proteoglycans are unique, multi-functional molecules with diverse structural and 
signalling roles within ligaments, and so far we have only touched on the role of proteoglycans in 
fibrillogenesis. Proteoglycans bind a variety of proteins and cell-surface receptors with high 
specificity, activating various cell signalling pathways within the matrix (Recently reviewed by Chen 
and Birk, 2013).(40) They are able to interact with fibrillar collagens as well as growth factors and 
cytokines, to regulate cellular proliferation and ECM remodelling. The important cell signalling roles 
of proteoglycans, in various pathways responsible for ECM turnover in the normal and injured state, 
should also be investigated in the future. 
 
TGF-β is suggested to have an important role in switching the healing process from normal to 
pathological,(350,351) and during tissue repair TGF-β is essential for the synthesis of a new matrix.(352) 
Both biglycan and decorin interact with all three isoforms of this regulatory cytokine, with several 
biological implications on cellular proliferation and differentiation.(260) TGF-β modulates 
inflammatory responses, angiogenesis, proteoglycan deposition, and stimulates collagen 
production.(353) Biglycan and decorin can significantly and dose-dependently decrease TGF-β induced 
gene expression in vitro,(241,259) but there is also conflicting reports that these SLRPs can in some 
cases increase the expression of TGF-β.(189) We can hypothesise that variants in the BGN and DCN 
genes (Chapter 2) may potentially alter the interactions of these proteins with TGF-β in the ECM. The 
involvement of TGF-β in the regulation of proteoglycan production, collagen synthesis, MMP 
synthesis and angiogenesis (206,240,353-355) (Figure 4.3) suggests that an alteration in the amount of TGF-
β present may modulate any one of these pathways and compromise ECM homeostasis and 
remodelling. TGF-β is evidently an important cytokine in the regulation of ECM remodelling and 
genetic variations within the genes encoding the three isoforms of TGF-β should be investigated for 
an association with ACL injury risk. The interaction between TGF-β and the proteoglycans should also 
be explored as was done with COL5A1 in Chapter 3. The functional consequences of such variants or 
interactions should then be examined in order to understand the dynamic between these molecules, 
disturbance of which may lead to injury susceptibly.  
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Figure 4.3: A schematic representation of the interaction of proteoglycans with TGF-β. 
Abbreviations: ACAN, aggrecan; BCN, biglycan; DCN, decorin; FMOD, fibromodulin; LUM, lumican; 
MMPs, matrix metalloproteinases; TGF-β, transforming growth factor-β; TIMPs, tissue inhibitor 
metalloproteinases; VCAN, versican.  
 
 
During the regulation of innate immunity functions, DAMPs, or ‘danger signals’, are recognised by 
the TLRs 2 and 4.(356,357) Biglycan and decorin,(264,358) versican,(359) and HA (360) are able to act as 
DAMPS, endogenous ligands of the TLRs. Under normal physiological conditions the proteoglycans 
are sequestered, but during tissue stress or damage, the ECM undergoes proteolytic digestion during 
remodelling, and the proteoglycans become soluble potent danger signals.(361) Although the 
proteoglycans all signal through the same TLRs, they activate different responses with different 
biological consequences.(242)  
 
Biglycan is an early response gene under inflammatory conditions and generates a rapid reaction.(361) 
Various pro-inflammatory cytokines and chemokines such as TNF-α and IL-1β are downstream 
effector molecules of biglycan-TLR2/4 signalling.(242) Biglycan is therefore capable of prompting 
autonomous sterile (non-pathogen-mediated) inflammation. Decorin is also an endogenous ligand 
for TLR2/4, which when bound triggers a cascade of cell signalling molecules such as the synthesis of 
cytokines, TNF-α and IL-12.(264) Decorin also inhibits TGF-β1 (independent of TLR2/4) and IL-10, 
immunosuppressive and anti-inflammatory molecules respectively, thereby creating a pro-
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cell signalling pathway by inducing the release of pro-inflammatory cytokines involved in the 
recruitment of macrophages and neutrophils,(362) however, lumican does not directly interact with 
TLR2/4 but rather with their adaptor molecule CD14.(363) Versican is also implicated in cell signalling 
and is suggested to act as a ligand to the TLR2/4 heterodimer and the CD14 adaptor in order to 
activate the production of pro-inflammatory cytokines.(359) 
 
The interaction of various proteoglycans with the TLR2/4 receptors highlights the versatile roles of 
these proteins that have signals embedded in their core and GAG chains. The role of proteoglycans 
in these pathways needs to be explored and the genes encoding molecules within the cell signalling 
pathways, involved in ECM remodelling following mechanical loading, should be investigated for 
associations with ACL injury susceptibility. This adds further complexity to the functions of 
proteoglycans, whose interactions with cell signalling genes may pose as possible therapeutic targets 
for inflammatory conditions.(242) 
 
The interaction of proteoglycans with the group of ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) proteinases can also be explored. The ADAMTS are a group of 
enzymes that, among other functions, are involved in regulating ECM homeostasis. Deficiency in 
ADAMTS5, a proteinase that interacts with aggrecan, results in abnormal tendon collagen 
organisation, affecting the biomechanical properties of the tendon.(364) ADAMTS14 and tissue 
inhibitor metalloproteinase 2 (TIMP2), have previously been associated with the age of onset, and 
risk of Achilles tendon pathology respectively.(365) The TIMPS are involved in the compositional 
regulation of the ECM, and thus the interactions of the proteoglycans, ADAMTS and TIMPS in ECM 
regulation is another process that could be investigated to add to the polygenic risk model for ACL 
injuries. 
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4.4 Clinical significance 
 
Understanding the biological dynamic interaction between proteins, such as proteoglycans with 
their receptors, and protein-protein interactions, will not only aid to elucidate the mechanisms that 
bring about an ACL injury, but these interactions could become therapeutic targets in the prevention 
and treatment of injury. An endothelial cell specific DS proteoglycan has previously been observed to 
be overexpressed in cancerous tumours and directly linked to the tumour progression. This 
proteoglycan has thus been identified as target in cancer therapies as well as a biomarker for 
inflammatory disorders and tumour progression.(366) Lubrican, a CS/KS proteoglycan, has too been 
identified as a target for immunotherapy in the treatment of various melanomas.(367,368) It is 
therefore plausible to consider proteoglycans as both biomarkers and targets in the prevention and 
treatment of multifactorial conditions such as ACL injuries.  
 
Proteoglycans will serve as an important part of a polygenic, multifactorial risk model that can be 
used to identify individuals that have an increased predisposition to sustaining an ACL injury. Those 
individuals may benefit from injury preventions strategies in the form of training techniques, as well 
as possible therapeutic interventions including personalised medicine. A recent study managed to 
inhibit the loss of proteoglycans from the matrix of bovine tendons using highly sulfated 
polysaccharides, thus highlighting the opportunity of targeting proteoglycans and interacting 
proteins in the prevention of injuries.(369) Interventions that are able to sustain ligament homeostasis 
and biomechanical composition in an otherwise compromised tissue, could prevent injuries. 
 
The potential of using proteoglycans and GAGs as injury biomarkers is already being fulfilled. KS 
levels in the synovial fluid of ACL injured knees are associated with the number of high-grade 
cartilage lesions,(370) and aggrecan and GAG content has been associated with the degree of tendon 
pathology.(308) Although proteoglycan biomarkers may be used to detect the severity of injury, 
magnetic resonance imaging is the best way to accurately diagnose an ACL injury without surgical 
incisions.  
 
With regards to using proteoglycans as a part of treatment following an ACL injury: intra-articular 
expression of proteoglycan 4 has recently been identified to protect against the development of OA 
in mice (371) by increasing lubrication within the joint. Individuals that have sustained an ACL rupture 
are at an increased risk of developing OA of the knee joint (32) and such treatments may be possible 
for humans in the future. TGF-β has been highlighted as an important cytokine in the regulation of 
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ECM remodelling in the injured and uninjured state; this molecule and its interactions with the 
proteoglycans may also serve as a therapeutic target in both prevention and treatment strategies. 
Following further research regarding the binding mechanisms of proteoglycans, the possibility also 
arises of pharmacologically influencing the inflammation experienced with injury,(163) and the 
interaction of proteoglycans with the TLRs could possibly be intervened. All these possibilities are 
however only plausible once the effects of the interactions of both proteoglycans and other effector 
molecules, with each other and with their receptors, are fully understood. 
 
A recent study investigated the potential benefit of platelet-rich plasma (PRP) on the graft healing 
process following ACL reconstruction in canines. PRP was observed to increase mRNA expression 
levels of COL1A1, COL3A1, TGF-β1, MMP1, BGN and TIMP-1, while DCN and MMP13 levels were 
decreased in ACL autographs, thereby positively affecting ECM remodelling following surgery.(372) 
PRP has thus been suggested as a potential treatment in improving ACL injury recovery following 
surgery by affecting the expression of various molecules that include the proteoglycans. Exogenous 
expression of proteoglycans may also aid the healing process following an ACL injury. 
 
Gene therapy is also a prospective treatment in the prevention and management of ACL injuries. 
This allows extra synthesis of certain molecules by introducing coding sequences that prolong the 
synthesis of bioactive anabolic agents.(373) Delivery mechanisms (vectors) are used to incorporate the 
coding sequence into the cell or matrix. The intra-articular injection of retroviral vectors carrying IL-1 
receptor agonist and soluble TNF-α receptor into rabbit knee joints emitted an anti-inflammatory 
and chondro-protective response in the injected and contralateral joint, improving the induced 
OA.(374) IL-1 receptor agonist has also been effectively used via gene therapy in the treatment of RA 
in a cohort of 472 patients.(375) Gene therapy thus appears to be an effective therapeutic 
intervention and similar methodology could be used in the treatment of ACL injuries to improve 
healing. A review by Nixon et al. (2007) highlights the positive results observed with gene therapy 
that combines cell supplementation and cells overexpressing certain growth factors, on 
musculoskeletal repair.(373) Some growth factors and cytokines used in gene therapy stimulated 
repair include, as mentioned, TGF-β, IL-1 receptor agonist and TNF-α, all of which are factors 
involved in ECM remodelling following mechanical loading.  
 
Increased knowledge of the molecular mechanisms of ACL injuries is of course required before gene 
therapies become possible. Once appropriate structural or signalling molecules with potential 
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therapeutic effects are identified, gene transfer vectors encoding such molecules can be transferred 
to the knee joint in trials, and the consequences observed.(376) 
 
In summary, the interactions of proteoglycans with their receptors as well as with other molecules, 
such as TGF-β, may present as possible drug targets in order to disrupt pathological mechanisms that 
lead to injury. The proteoglycans however interact with an array of molecules in the regulation of 
ECM remodelling and other complex cell signalling pathways such as apoptosis and angiogenesis. 
Only a few interactions have been mentioned in this dissertation as directions for future research 
and the possible clinical implications of these interactions as drug targets, but there is much more 
knowledge to be gained regarding the dynamic role of proteoglycans in the ligament tissue. It is 
particularly important to identify pharmacological targets that may aid in the treatment of ACL 
injuries by influencing ECM remodelling, fibrillogenesis and ligament healing as this ligament 
typically has a poor healing capacity.(73)  
 
Only once we advance our knowledge regarding the contribution of each molecule to ligament 
homeostasis and the mechanisms that result in ACL injury may potential treatments become a 
reality for human patients. Genetics and the results of this dissertation have however taught us that 
individual genetic variation in sequence signatures could result in predisposition to injury due to 
disruption of ligament properties via improper regulation of various protein expression or protein 
interactions. Different individuals will thus have varying factors that are either lacking within their 
ligaments or factors that are being over-expressed. With greater understanding, these differences 
could be targeted in the prevention or treatment of injury, but inter-individual genetic variation is 
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4.5 Concluding remarks 
 
In conclusion, this dissertation identified independent associations between the ACAN and DCN 
genes, and ACL injury susceptibility. Regions overlapping ACAN, BGN, LUM and DCN, and interactions 
between the proteoglycan genes and COL5A1 were also implicated in the risk of injury. This implies 
that the proteoglycans, and their role in the regulation of ligament structure organisation and 
fibrillogenesis, may be a pathway involved in the mechanism of ACL injuries. The results of this 
dissertation should be repeated in an independent population, and the regions within the 
proteoglycan genes implicated in this dissertation should be further interrogated. 
 
With further research, the results presented may have a potential impact on the prevention and 
treatment of ACL injuries in the future. Polymorphisms within the proteoglycan genes can 
potentially be used together with previously associated polymorphisms in a polygenic risk profile to 
determine which individuals are at a greater risk of sustaining an ACL injury, and prevention 
strategies put in place. It may also be possible to target proteoglycans and their interactions, in the 
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 Study information 
 
THE GENETIC BASIS OF EXERCISE-INDUCED LIGAMENT INJURY 
 
Although there is a high incidence of ligament injuries as a result of participation in exercise and 
sporting activities, the cause(s) of these injuries are poorly understood. Some researchers have 
suggested that there is a genetic component to exercise-induced ligament injuries. In an attempt to 
determine whether there is a genetic basis for ligament pathology, we are interested in studying 
whether certain genes are associated with ligament injuries. This project is being done in 
collaboration with the UCT/MRC Research Unit for Exercise Science and Sports Medicine within 
the Department of Human Biology of the University of Cape Town. 
 
You will be required to visit the Sports Science Institute of South Africa (SSISA) in Boundary Road, 
Newlands. During the visit, which should take 15 minutes, you will be asked to donate 5ml (1 
teaspoon) of a blood sample for DNA analysis. You will also be required to complete personal 
particulars, sporting details, medical history and stretching and warm up questionnaires. 
 
All the information retrieved from this study will be treated with the strictest confidentiality and will 
be used only for scientific research purposes. Your name and personal particulars will not be 
released under any circumstances and all data will be analysed anonymously. Your DNA sample 
will be destroyed on completion of the study on the genetic basis of ligament injury. You are also 
free to request that your DNA sample be destroyed before the completion of the study. 
 
If you are part of the ligament pathology group, we would appreciate it if you could help us by 
recruiting two other people of same (or similar) age whom you know and who has trained without 
suffering any ligament or tendon injuries for the control group. 
 
We will keep you informed about the outcomes of this study and look forward to working together 
with you. If you have any questions about this study, please feel free to contact us at:- 
 
Dr Mike Posthumus, PhD 
(021) 650 4572 
michael.posthumus@uct.ac.za 
 
Dr Alison September, PhD 





Prof Malcolm Collins, PhD 
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 Informed Consent for adults >18 years 
 




I, the undersigned, have been fully informed about the UCT/MRC Research Unit for Exercise Science 
and Sports Medicine within the Department of Human Biology of the University of Cape Town’s study 
on the genetic basis of exercise induced chronic ligament pathology. I have agreed to donate five 
millilitres of venous blood or a buccal mouthwash sample, which will be used for the extraction and 
analysis of genetic material (DNA). I have also agreed to complete personal particulars, sporting 
participation, medical history, stretching and warm up questionnaires and understand that all the 
information that is collected during the study will be treated with the strictest confidentiality and will 
only be used for scientific research purposes. I also understand that my name and personal 
particulars will be not released under any circumstances and that all data will be analysed 
anonymously. 
 
I agree to participate in the study and I have been informed that I will be free to withdraw from the 
study at any time if I so wish. I understand that my DNA sample will be destroyed on completion of the 
study on the genetic basis of ligament pathology. I also understand that I will be free to request that 
my DNA sample be destroyed before the completion of the study. 
 
I understand that the DNA will be genotyped (analysed) for variations (polymorphisms) within genes 
relating to the genetic basis of ligament injuries. I understand that whilst there is no direct benefit to 
myself, if a genetic predisposition for ligament injuries can be established, then future generations will 
be able to establish their risk for this condition. This may allow better prevention and treatment 
options in the future. I understand that I will receive the overall results of the study. I have read (or 
where appropriate, have had read to me) and understand the information about this study, and any 
questions I have asked have been answered to my satisfaction. I agree to participate in the study, 
realising that I have the right to request that my DNA sample be destroyed at any time. I agree that 
research data provided by me or with my permission during the project may be included in a thesis, 
presented at conferences and published in journals on the condition that either my name not any 
other identifying information is used. 
 
FULL NAME OF SUBJECT:           _________________________________ 
 
SUBJECT’S SIGNATURE:              _________________________________ 
 
DATE:       _________________________________   
 
INVESTIGATOR :                            _________________________________ 
                 
INVESTIGATOR’S SIGNATURE:  _________________________________  
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 Informed assent and consent for minors <18 years 
 
GENETIC BASIS OF EXERCISE-INDUCED LIGAMENT INJURY 
 
INFORMED ASSENT (for minors <18 years) 
 
I, the undersigned, have been fully informed about the UCT/MRC Research Unit for Exercise Science 
and Sports Medicine within the Department of Human Biology of the University of Cape Town’s study 
on the genetic basis of exercise-induced chronic ligament pathology. I have agreed to donate five 
millilitres of venous blood or a buccal mouthwash sample, which will be used for the extraction and 
analysis of genetic material (DNA). I have also agreed to complete personal particulars, sporting 
participation, medical history, stretching and warm up questionnaires and understand that all the 
information that is collected during the study will be treated with the strictest confidentiality and will 
only be used for scientific research purposes. I also understand that my name and personal 
particulars will be not released under any circumstances and that all data will be analysed 
anonymously.   
 
I agree to participate in the study and I have been informed that I will be free to withdraw from the 
study at any time if I so wish. I understand that my DNA sample will be destroyed on completion of the 
study on the genetic basis for ligament pathology. I also understand that I will be free to request that 
my DNA sample be destroyed before the completion of the study. 
 
I understand that the DNA will be genotyped (analysed) for variations (polymorphisms) within genes 
relating to the genetic basis of ligament injuries. I understand that whilst there is no direct benefit to 
myself, if a genetic predisposition for ligament injuries can be established, future generations will be 
able to establish their risk for this condition. This may allow better prevention and treatment options in 
the future. I understand that I will receive the overall results of the study. I have read (or where 
appropriate, have had read to me) and understand the information about this study, and any 
questions I have asked have been answered to my satisfaction. I agree to participate in the study, 
realising that I have the right to request that my DNA sample be destroyed at any time. I agree that 
research data provided by me or with my permission during the project may be included in a thesis, 
presented at conferences and published in journals on the condition that either my name not any 
other identifying information is used. 
 
FULL NAME OF PARTICIPANT: ________________________ 
PARTICIPANT’S SIGNATURE:  ________________________ 
DATE:      ________________________                 
INVESTIGATOR:   ________________________ 
INVESTIGATOR’S SIGNATURE: ________________________ 
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PARENTAL/GUARDIAN CONSENT (for minors <18 years) 
 
I, the undersigned and parent/ legal guardian of ______________________________, have been 
fully informed about the UCT/MRC Research Unit for Exercise Science and Sports Medicine within 
the Department of Human Biology of the University of Cape Town’s study on the genetic basis of 
exercise-induced chronic ligament pathology. I, the parent/ legal guardian, hereby give written 
permission that my child may participate in this study. I give permission for my child to donate five 
millilitres of venous blood or a buccal mouthwash sample, which will be used for the extraction and 
analysis of genetic material (DNA). In addition, I give permission that my child may complete personal 
particulars, sporting participation, medical history, stretching and warm up questionnaires and 
understand that all the information that is collected during the study will be treated with the strictest 
confidentiality and will only be used for scientific research purposes. I also understand that all our 
names and personal particulars will be not released under any circumstances and that all data will be 
analysed anonymously.  
 
I agree that I have been informed that my child will be free to withdraw from the study at any time if I 
so wish. I understand that the DNA sample will be destroyed on completion of the study on the 
genetic basis for ligament pathology. I also understand that I will be free to request that the DNA 
sample be destroyed before the completion of the study. 
 
I understand that the DNA will be genotyped (analysed) for variations (polymorphisms) within genes 
relating to the genetic basis of ligament injuries. I understand that whilst there is no direct benefit to 
myself, if the susceptibility factors for ligament injuries can be established, future generations will be 
able to establish their risk for this condition. This may allow better prevention and treatment options in 
the future. I understand that I will receive the overall results of the study. I have read (or where 
appropriate, have had read to me) and understand the information about this study, and any 
questions I have asked have been answered to my satisfaction. I agree for my child to participate in 
the study, realising that I have the right to request that the DNA sample be destroyed at any time. I 
agree that research data provided by my child or with my permission during the project may be 
included in a thesis, presented at conferences and published in journals on the condition that either of 
our names or any other identifying information is used. 
 
The University of Cape Town (UCT) has an appropriate insurance policy to cover payment for any 
trial-related injury. This study has obtained ethical approval from the UCT Faculty of Health Sciences 
Research Ethic Committee (FHS REC). If you have any complaints or queries that the investigator 
has not been able to answer to your satisfaction, you may contact Prof. Marc Blockman from the FHS 
REC on telephone number 021 406 6452. 
 
FULL NAME OF PARENT /LEGAL GUARDIAN:  ______________________________  
PARENT /LEGAL GUARDIAN’S SIGNATURE:  ______________________________ 
DATE:       ______________________________ 
INVESTIGATOR:     ______________________________ 
INVESTIGATOR’S SIGNATURE:   ______________________________ 
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 Participant Questionnaire 
 
GENETIC BASIS OF LIGAMENT INJURY QUESTIONNAIRES 
 
 
A. PERSONAL PARTICULARS 
Surname  








E-mail address  Phone (day time)  
Date of birth Y  Y  Y  Y  /  M  M  /  D  D  Cell   
Height (cm) 
 
Gender Male  Female  
Weight (kg) Pre-Injury: Current: 
Ethnic group 
(Only Required and 
Used for Research 
Purposes) 
Black/African    White    Indian    




(eg Xhosa, Dutch, 
Zulu, German, 
Italian) 
Father Unknown   
Mother Unknown   
Country of Birth 
 
Dominant Hand Left      Right      Both  
Dominant 




Yes (Current)   Yes (Ex-smoker)   No, never   
If yes, Number of 
years _________ 
If stopped, when _______________ 
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 (If you participate or have participated in more than 6 sports, please complete 
additional Sporting Details Questionnaires, Part B) 
 
 
B. SPORTING DETAILS  
Please record your sporting activities in order of importance 
Type of sport(s) you have 
participated in (please name) 
Main sport 1 Other sport 2 Other sport 3 
   
Current or past participation Current  Past  Current  Past  Current  Past  
Year started participation 
   
Number of years involved in the 
sport 
   
Position played prior to injury (if 
appropriate) 
   
Playing level prior to injury (if 
appropriate) 
   
Number of years played prior to 
the injury. 
   
 
 
Type of sport(s) you have 
participated in (please name) 
Other sport 4 Other sport 5 Other sport 6 
   
Current or past participation Current  Past  Current  Past  Current  Past  
Year started participation 
   
Number of years involved in the 
sport 
   
Position played prior to injury (if 
appropriate) 
   
Playing level prior to injury (if 
appropriate) 
   
Number of years played prior to 
the injury. 



















C. ANTERIOR CRUTIATE LIGAMENT INJURY DETAILS 
 
Date of ACL injury?  
Which side was injured? 
 Left                       Right             Both         
To what extent was your 
ligament ruptured?  Complete       Partial      None    Unknown 
Investigation done to confirm 
the diagnosis  MRI                                   Surgery 






       I-----------------------------------------------------------------------I 
No pain                                                                       Pain as bad as it can be 
 
How was the ACL ruptured? 
 
 
 Direct impact (directly to the injured knee)     
 Twisting and bending with indirect contact (i.e. contact  
elsewhere on the body) 
 Twisting and bending without contact (no external contact) 
 Skiing 
 Other (please specify)…….…………………………………… 
 
Please describe the exactly 
how the injury occurred (If 
uncertain please state that you 





What was the initial treatment? 




 Ice application 












What are your current 
symptoms? (You may tick 
more than one block.) 
 
 Pain 
 Swelling      
 Instability 
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 Limited to non-weight bearing exercise      
 Limited, not to same level as pre-injury 
 Full participation         
If you are able to recall, what 
were the weather and pitch 
conditions like at the time of 
injury? 
 Wet and soft ground 
 Dry, but soft ground     
 Dry and firm ground 
 Wet, but firm ground     
 Other……………………………………………………..  
Associated injuries? 
 Meniscal tear 
 MCL tear 
 Other ligament tear 
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D. HISTORY OF OTHER LIGAMENT AND TENDON INJURIES IN THE PAST 
Have you ever injured a ligament in the 
past? Yes  No               
If yes, please specify which ligaments? 
(You may tick more than one block, 
please select either L (left) or R (right)) 
 
                                       L   R                                          L   R 
Knee (ACL)                Wrist ligaments     
Knee (MCL)                Finger ligaments   
Ankle lateral ligaments    Knee (PCL)    
Spinal  ligaments              Knee (LCL)                       
Shoulder ligaments         Ankle medial ligaments    
Elbow ligaments               Other ligaments                
To your knowledge, have any other 
members of your family suffered from 
any ligament injury? 
Yes  No  
 




 Son / daughter 
 Other family member………………….…. 
and condition: Please choose ligament 
injury from the list above 
…………………………………………………. 
Have you ever injured a tendon in the 
past? Yes  No  
If yes, please specify which tendon? 
(You may tick more than one block, 
please select either L (left) or R (right)) 
Foot and ankle: 
                                       L   R 
Achilles tendon    
Tibialis posterior               
Plantar fascia                   
Knee: Patellar tendon    
Elbow and wrist: Wrist extensor tendons   
Shoulder: 
Subscapularis        
Supraspinatus                
Infraspinatus                
Teres minor                  
Other:…………………………………………………………….. 
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To your knowledge, have any other 
members of your family suffered from 
any tendon pathology? 
Yes  No  
 




 Son / daughter 
 Other family member:…….………………. 
Condition: Please choose tendon injury from 
the list above 
…….……………………………………………. 
Have you ever suffered from any of the 
following joint capsule injuries? 
 Acute shoulder dislocation 
 Chronic shoulder instability 
 Chronic ankle instability 
 Other: _______________________________________ 






























 _________________________________________________________________________________   
136 
  
E.  MEDICAL HISTORY 
 
Do you currently suffer from any of these medical conditions: 
 High Blood Pressure 
 Emphysema 
 Malignant disease (cancer) 
 
If Yes, what type?  
________________________
_ 
 Angina/Heart Attack 
 Rheumatoid arthritis 
 Elevated Blood Cholesterol 
 Diabetes mellitus 
 Renal disease 
 
 Asthma 
 Osteoarthritis (wear & tear) 
 Adrenal disorders 
 Thyroid disorders 
 Amyloidosis 
Do you currently suffer from any other 
Connective Tissue & Rheumatological 
Diseases & Disorders? 
Yes   No  If Yes, please select from the list below 
List of some Connective Tissue and/or Rheumatic Diseases and Disorders 
 Ankylosing Spondylitis 
 Aspartylglycosaminuria (AGU) 
 Behcet’s Syndrome 
 Crohn’s Disease 
 Discoid Lupus Erythematosus 
 Ehlers-Danlos syndrome (EDS) 
 Eosinophilic Fascitis 
 Giant Cell (Temporal) Arthritis 
 Gout 
 Hypersentive Vasulatis 
 
 Lipid Storage Diseases 
 Marfan Syndrome 
 Menkes Kinky Hair Syndrome 
 Mucopolysaccharidoses 
 Myopathies and Dystrophies  
 Ochronosis (Homocystinuria) 
 Osteogenesis imperfecta (OI) 
 Polyarteritis Nodosa 
 Polymyalgia Rheumatica 
 Polymyositis & Dermatomyositis 
 
 Pseudogout 
 Reactive Arthritis 
 Reiter’s Syndrome 
 Relapsing Polychrondritis 
 Scleroderma 
 Sjogren’s Syndrome 
 Systemic Lupus Erythematosus (SLE) 
 Systemic Sclerosis 






What surgical operations have you 








At what age did you start 
menstruating? (years) 
 
Are you currently using any type of 
contraception?  Yes      No 
If Yes, what type of contraception are 
you using?  Pill       Injection     IUD 
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Are you currently? 
 Pre-menopausal  (±12 cycles per year at intervals of 23–  
33 days & bleeding lasts 3-7 days) 
 Menopausal   (cycles are irregular and less frequent) 
 Post-menopausal   (no longer menstruating) 
Family History 
Do any other members of your family 
suffer from elevated blood cholesterol? Yes   No  
 




 Son / daughter 
 Other relative:…….…………..………. 
 
Is there any history of arthritis in your 
family? Yes   No  




 Son / daughter 
 Other relative:…….……………..………. 
& What type of aethritis? 
Rheumatoid         
Osteoarthritis       





Drug and Allergy History 
If yes, how long ago (or how many times, where applicable) 
did you use the medication? 
Have you ever used oral 
corticosteroids (cortisone tablets)? Yes  No  
 3 months  6 months 
 12 months  24 or more months 
Have you ever been given an injection 
with corticosteroids? Yes  No  
 3 months  6 months 
 12 months  24 or more months 
Have you ever been given an injection 
of corticosteroids in or around a 
tendon? 
Yes   No  
 Once  Twice 
 3 times  >3 times 
Have you ever used anabolic steroids? Yes   No  
 3 months  6 months 
 12 months  24 or more months 
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Have you ever used fluoroquinoline 
antibiotics? Yes   No  
 3 months       6 months 
 12 months     24 or more months 












 CPL ALLIANCE 
CIPROFLOXACIN 
 DYNAFLOC 
 FLOXIN  
 MAXAQUIN 
 NOROXIN 
 ORPIC  
 










What medication, if any, are you 
currently using? (please list) 
 
 





F. OCCUPATIONAL DETAILS 
What is your current occupation? 
 
What was your occupation prior to injuring your 
ligament? 
 
Prior to injury, did your occupation involve lower limb 
activity? 
 
 Yes      No 
If yes please indicate which legs. 
Right leg       Both legs   
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 DNA Extraction 
 
As described by Lahiri and Nurnberger (1991) and modified by Mokone et al. (2005). 
 
The 5ml of collected blood was transferred from the ethylenediaminetetraacetic acid (EDTA) 
vacutainer tube to a sterile 15ml polypropolene tube. 2 volumes (10ml) of TKM1 buffer (see 
solutions below) containing 2.5% NP40 was added to the polypropolene tube. The tube was mixed 
by inversion several times, and incubated at room temperature for 10 minutes in order to enhance 
the haemolysis of red blood cells. Centrifugation at 3000rpm at room temperature for 10 minutes 
then allows the formation of a pellet of white blood cells at the bottom of the tube, and the 
supernatant of red blood cells may be discarded. This occurs because the heavy white blood cells 
gravitate to the bottom of the tube during centrifugation, whereas the haemolysed red blood cells 
are lighter and so remain in the supernatant. 1 volume (5ml) of TKM1 buffer was added to the pellet 
of white blood cells and the tube was shaken vigorously to re-suspend the pellet and wash it. The 
tube was then centrifuged at 3000rpm at room temperature for 10 minutes and the supernatant 
discarded once again. The wash with TKM1 buffer, centrifugation and discarding of supernatant was 
repeated until the pellet at the bottom of the tube was clean and white. 800µl of TKM2 buffer and 
50µl of 10% SDS (see solutions) was added to the pellet. The solution was then shaken again to assist 
the lyses of the white blood to release the DNA. The solution was then incubated at 55˚C for 1 hour 
to dissolve the pellet and free the contents of the white blood cells. 150µl of 5M NaClO4 (see 
solutions) was added, followed by 500µl of chloroform. The solution was vortexed and transferred to 
1.5ml microfuge tubes. The tubes were centrifuged at room temperature for 5 minutes at 1300rpm, 
and 500µl of the top aqueous phase containing the DNA was transferred to a new sterile 1.5ml 
microfuge tube. 1ml of absolute ethanol was added, and the tube inverted until the DNA 
precipitated. The tube was centrifuged once again at 1300rpm at room temperature for 5-10 
minutes, and the supernatant carefully poured off leaving behind the pellet of DNA at the bottom of 
the tube. The pellet was allowed to air dry until being re-suspended in 100µl of 1XTE buffer (see 
solutions). The tube was incubated at 65˚C for 15 minutes in a heating block, after which the DNA 









































 Molecular Weight Final concentration Amount for 500ml 
Tris-HCl 121.00 10mM 0.6056g 
KCl 74.56 10mM 0.3728g 
MgCl2.6H2O 203.20 10mM 1.016g 
EDTA 372.24 2mM 0.372g 
dH2O   To 500ml 
 Molecular Weight Final concentration Amount for 200ml 
Tris-HCl 121.00 10mM 0.242g 
KCl 74.56 10mM 0.149g 
MgCl2.6H2O 203.20 10mM 0.406g 
EDTA 372.24 2mM 0.1488g 
NaCl 58.44 0.4M 4.675g 
dH2O   To 200ml 
 Final concentration Amount for 200ml 
SDS (10x) 10% 20g 
dH2O  To 200ml 
 Molecular Weight Final concentration Amount for 100ml 
NaClO4 122.4 5M 61.2ml 
dH2O   To 100ml 
 Molecular Weight Final concentration Amount for 100ml 
Tris-HCl 121.00 10mM 0.121g 
EDTA 372.24 1mM 0.037g 
dH2O   To 100ml 
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 Supplementary Tables 
 
 
Supplementary Table 1: P values of the genotype effect, of the variants within the aggrecan 
(ACAN), biglycan (BGN), decorin (DCN), fibromodulin (FMOD) and lumican (LUM) genes, on 
descriptive measures of participants. 
 
 
Significant p values are noted in bold. 







Age Sex Weight Height BMI COB 
ACAN 
      rs2351491 0.245 0.220 0.521 0.910 0.263 0.347 
rs1042631 0.839 0.033 0.996 0.329 0.748 0.528 
rs1516797 0.605 0.812 0.528 0.905 0.670 0.518 
BGN - MALE PARTICIPANTS 
rs1126499 0.777  0.966 0.098 0.086 0.153 
rs1042103 0.274  0.318 0.247 0.206 0.455 
BGN - FEMALE PARTICIPANTS 
rs1126499 0.092  0.949 0.672 0.984 0.621 
rs1042103 0.923  0.170 0.607 0.703 0.571 
DCN       
rs13312816 0.125 0.970 0.574 0.748 0.572 0.933 
rs516115 0.780 0.549 0.395 0.669 0.276 0.606 
FMOD       
rs7543148 0.308 0.967 0.338 0.466 0.144 0.758 
rs10800912 0.693 0.866 0.785 0.259 0.489 0.832 
LUM       
rs2268578 0.875 0.753 0.924 0.204 0.235 0.274 







Supplementary Table 2: Genotype and minor allele frequency distributions, as well as the Hardy-Weinberg equilibrium (HWE) values, of the 
sequence variants investigated within the aggrecan (ACAN), biglycan (BGN), decorin (DCN), fibromodulin (FMOD) and lumican (LUM) genes in 
all participants, male and female control (CON) and anterior cruciate ligament rupture (ACL) groups, as well as the ACL subgroup with a non-




All participants  Male 
 
Female 
CON ACL NON  CON ACL NON  CON ACL NON 
ACAN            
rs2351491     




N 233 225 125  144 165 93  89 60 32 
CC  12.0 (28) 15.6 (35) 16.0 (20)  12.5 (18) 17.6 (29) 17.2 (16)  11.2 (10) 10.0 (6) 12.5 (4) 
CT  47.2 (110) 45.3 (102) 48.8 (61)  50.7 (73) 44.2 (73) 47.3 (44)  41.6 (37) 48.3 (29) 53.1 (17) 
TT  40.8 (95) 39.1 (88) 35.2 (44)  36.8 (53) 38.2 (63) 35.5 (33)  47.2 (42) 41.7 (25) 34.4 (11) 
p Value  0.547 0.437   0.365 0.598   0.717 0.445 
HWE 0.773 0.573 1.000  0.478 0.335 0.833  0.638 0.777 0.713 
C allele 35.6 38.2 40.4  37.9 39.7 40.7  32.0 34.2 39.1 
p Value  0.415 0.208   0.638 0.511   0.699 0.308 
rs1042631     




N 233 227 126  144 166 94  89 61 32 
TT  3.0 (7) 4.4 (10) 4.0 (5)  2.8 (4) 4.2 (7) 3.2 (3)  3.4 (3) 4.9 (3) 6.3 (2) 
TC  28.8 (67) 35.7 (81) 36.5 (46)  34.0 (49) 38.0 (63) 40.4 (38)  20.2 (18) 29.5 (18) 25.0 (8) 
CC  68.2 (159) 59.9 (136) 59.5 (75)  63.1 (91) 57.8 (96) 56.4 (53)  76.4 (68) 65.6 (40) 68.8 (22) 
p Value  0.168 0.254   0.564 0.575   0.349 0.635 
HWE 1.000 0.709 0.796  0.598 0.519 0.388  0.184 0.684 0.276 
T allele 17.4 22.3 22.2  19.8 23.2 23.4  13.5 19.7 18.8 
p Value  0.064 0.115   0.305 0.346   0.151 0.310 
rs1516797     




N 233 227 126  144 166 94  89 61 32 
TT  51.1 (119) 42.3 (96) 47.6 (60)  50.0 (72) 44.0 (73) 51.1 (48)  52.8 (47) 37.7 (23) 37.5 (12) 
TG  42.9 (100) 46.7 (106) 42.9 (54)  44.4 (64) 44.0 (73) 40.4 (38)  40.5 (36) 54.1 (33) 50.0 (16) 
GG  6.0 (14) 11.0 (25) 9.5 (12)  5.6 (8) 12.1 (20) 8.5 (8)  6.7 (6) 8.2 (5) 12.5 (4) 
p Value  0.059 0.451   0.122 0.617   0.188 0.275 
HWE 0.321 0.662 1.000  0.299 0.863 1.000  1.000 0.261 1.000 
G allele 27.5 34.4 31.0  27.8 34.0 28.7  27.0 35.3 37.5 
p Value   0.024 0.325   0.093 0.823   0.125 0.114 








All participants  Male 
 
Female 
CON ACL NON  CON ACL NON  CON ACL NON 
BGN            
rs1126499     




N     143 166 94  88 61 32 
CC      51.6 (74) 48.2 (80) 48.9 (46)  23.9 (21) 18.0 (11) 21.9 (7) 
CT          55.7 (49) 45.9 (28) 43.8 (14) 
TT      48.3 (69) 51.8 (86) 51.1 (48)  20.5 (18) 36.1 (22) 34.4 (11) 
p Value      0.533 0.672   0.105 0.278 
HWE         0.394 0.790 0.496 
T allele     48.3 51.8 51.1  48.3 59.0 56.3 
P Value      0.378 0.549   0.068 0.276 
rs1042103     




N     143 166 94  89 61 32 
GG     55.9 (80) 60.8 (101) 59.6 (56)  38.2 (34) 26.2 (16) 28.1 (9) 
GA          49.4 (44) 54.1 (33) 56.3 (18) 
AA     44.1 (63) 39.2 (65) 40.4 (38)  12.4 (11) 19.7 (12) 15.6 (5) 
p Value      0.383 0.580   0.226 0.584 
HWE         0.652 0.612 0.718 
A allele     44.1 39.2 40.4  37.1 46.7 43.8 
p Value      0.218 0.434   0.095 0.348 
DCN            
rs13312816     




N 234 227 126  144 166 94  90 61 32 
AA 1.3 (3) 0.0 (0) 0.0 (0)  1.4 (2) 0.0 (0) 0.0 (0)  1.1 (1) 0.0 (0) 0.0 (0) 
AT  16.2 (38) 15.4 (35) 15.9 (20)  14.6 (2) 17.5 (29) 17.0 (16)  18.9 (17) 9.8 (6) 12.5 (4) 
TT  82.5 (193) 84.6 (192) 84.1 (106)  84.0 (121) 82.5 (137) 83.0 (78)  80.0 (73) 90.2 (55) 87.5 (28) 
p Value  0.221 0.438   0.256 0.465   0.214 0.584 
HWE 0.437 0.372 1.000  0.281 0.612 1.000  1.000 1.000 1.000 
A allele 9.4 7.7  7.9   8.7 8.7 8.5  10.6 4.9 6.3 
p Value   0.359 0.510   0.981 0.949   0.081 0.311 
rs516115            
N 234 227 126  144 166 94  90 61 32 
AA 45.7 (107) 45.4 (103) 46.8 (59)  50.0 (72) 42.2 (70) 40.4 (38)  38.9 (35) 54.1 (33) 65.6 (21) 
AG 43.2 (101) 44.5 (101) 42.9 (54)  40.3 (58) 44.6 (74) 45.7 (43)  47.8 (43) 44.3 (27) 34.4 (11) 
GG 11.1 (26) 10.2 (23) 10.3 (13)  19.7 (14) 13.3 (22) 13.8 (13)  13.3 (12) 1.6 (1) 0.0 (0) 
p Value  0.926 0.965   0.334 0.305   0.021 0.012 
HWE 0.767 0.881 1.000  0.692 0.736 1.000  1.000 0.156 0.554 
G allele 32.7 32.4 31.8  29.9 35.5 36.7  37.2 23.8 17.2 
p Value   0.919 0.796   0.133 0.120   0.014 0.003 








All participants  Male 
 
Female 
CON ACL NON  CON ACL NON  CON ACL NON 
FMOD            
rs7543148     




N 232 226 125  143 165 93  89 61 32 
GG 4.7 (11) 3.1 (7) 3.2 (4)  5.6 (8) 2.4 (4) 3.2 (3)  3.4 (3) 4.9 (3) 3.1 (1) 
GA 31.5 (73) 28.3 (64) 26.4 (33)  29.4 (42) 29.7 (49) 28.0 (26)  34.8 (31) 24.6 (15) 21.9 (7) 
AA 63.8 (148) 68.6 (155) 70.4 (88)  65.0 (93) 67.9 (112) 68.8 (64)  61.8 (55) 70.5 (43) 75.0 (24) 
p Value  0.458 0.428   0.355 0.657   0.392 0.389 
HWE 0.554 0.820 0.744  0.303 0.788 0.728  0.755 0.355 0.481 
G allele 20.5 17.3 16.3  20.3 17.3 17.2  20.8 17.2 14.1 
p Value  0.214 0.186   0.340 0.406   0.441 0.270 
rs10800912            
N 233 225 124  144 164 92  89 61 32 
CC 3.0 (7) 3.1 (7) 3.2 (4)  3.5 (5) 3.1 (5) 4.4 (4)  2.3 (2) 3.3 (2) 0.0 (0) 
CT 23.2 (54) 27.1 (61) 24.2 (30)  22.9 (33) 28.1 (46) 25.0 (23)  23.6 (21) 24.6 (15) 21.9 (7) 
TT 73.8 (172) 69.8 (157) 72.6 (90)  73.6 (106) 68.9 (113) 70.7 (65)  74.2 (66) 72.1 (44) 78.1 (25) 
p Value  0.616 0.968   0.586 0.868   0.914 0.671 
HWE 0.295 0.637 0.487  0.316 0.787 0.275  0.676 0.618 1.000 
C allele 14.6 16.7 15.3  14.9 17.1 16.9  14.0 15.6 10.9 
p Value  0.387 0.794   0.470 0.576   0.713 0.668 
LUM            
rs2268578     




N 234 227 126  144 166 94  90 61 32 
TT  2.6 (6) 1.3 (3) 0.8 (1)  3.5 (5) 1.2 (2) 1.1 (1)  1.1 (1) 1.6 (1) 0.0 (0) 
TC 26.5 (62) 25.6 (58) 23.8 (30)  23.6 (34) 27.1 (45) 25.5 (24)  31.1 (28) 21.3 (13) 18.8 (6) 
CC 70.9 (166) 73.1 (166) 75.4 (95)  72.9 (105) 71.7 (119) 73.4 (69)  67.8 (61) 77.1 (47) 81.3 (26) 
p Value  0.598 0.412   0.343 0.497   0.406 0.325 
HWE 1.000 0.585 0.689  0.329 0.525 1.000  0.445 1.000 1.000 
T allele 15.8 14.1 12.7  15.3 14.8 13.8  16.7 12.3 9.4 
p Value   0.466 0.261   0.857 0.663   0.295 0.218 
 
Genotype and minor allele frequencies are reported as a percentage with the number of observations (n) in parenthesis. The total number of samples 
genotyped (N) is also indicated. ACL and NON p values are the allelic differences between the ACL and CON, and NON and CON groups respectively.
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